<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Farmacogn</journal-id><journal-id journal-id-type="iso-abbrev">Rev Bras Farmacogn</journal-id><journal-title-group><journal-title>Revista Brasileira De Farmacognosia</journal-title></journal-title-group><issn pub-type="ppub">0102-695X</issn><issn pub-type="epub">1981-528X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7537782</article-id><article-id pub-id-type="publisher-id">104</article-id><article-id pub-id-type="doi">10.1007/s43450-020-00104-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Coronaviruses and Nature&#x02019;s Pharmacy for the Relief of Coronavirus Disease 2019</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6946-0724</contrib-id><name><surname>Chinsembu</surname><given-names>Kazhila C.</given-names></name><address><email>kchinsembu@unam.na</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.10598.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 1014 6159</institution-id><institution>Faculty of Science, Department of Biological Sciences, </institution><institution>University of Namibia, </institution></institution-wrap>Private Bag 13301, Windhoek, Namibia </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>10</month><year>2020</year></pub-date><fpage>1</fpage><lpage>19</lpage><history><date date-type="received"><day>3</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Sociedade Brasileira de Farmacognosia 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><title>Graphical abstract</title><p id="Par2">
<graphic position="anchor" xlink:href="43450_2020_104_Figa_HTML" id="MO1"/>
</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Human respiratory infection</kwd><kwd>Natural inhibitors</kwd></kwd-group><funding-group><award-group><funding-source><institution>None</institution></funding-source><award-id>N/A</award-id></award-group></funding-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Coronaviruses (CoVs) cause acute and chronic respiratory, enteric, and central nervous system diseases in many species of animals including humans. While the history of CoVs dates as far back as the 1940s, identification of the first human CoVs (HCoVs) as causative agents of mild respiratory infections was reported in the 1960s. These HCoVs were named human CoV 229E (HCoV-229E) and HCoV-OC43 (Pillaiyar et al. <xref ref-type="bibr" rid="CR92">2020</xref>). The replication and pathogenesis of CoVs were actively studied by virologists in the 1970s, leading to the discovery of four other human CoVs, namely HCoV-Hong Kong University 1 (HCoV-HKU1), human coronavirus-NL63 (HCoV-NL63), severe acute respiratory syndrome (SARS)-CoV, and Middle East respiratory syndrome (MERS)-CoV (Pillaiyar et al. <xref ref-type="bibr" rid="CR92">2020</xref>).</p><p id="Par4">SARS is a highly contagious and often fatal respiratory infection. HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 are ubiquitous and cause approximately one-third of common cold in humans. HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 strains are usually associated with mild, self-limiting upper respiratory tract infections, such as the common cold (Andersen et al. <xref ref-type="bibr" rid="CR1">2020</xref>). However, subtypes HCoV-229E, HCoV-OC43, HCoV-HKU1, and HCoV-NL63 can cause life-threatening pneumonia and bronchitis in the elderly and immunologically compromised individuals including those undergoing chemotherapy and persons living with HIV/AIDS.</p><p id="Par5">Indeed, before the discovery of SARS-CoV, two coronaviruses, HCoV-229E and HCoV-OC43, were known to infect humans, but they caused only self-limiting upper respiratory tract infections (30% of the common colds), and had never been reported to cause severe illness (Kuba et al. <xref ref-type="bibr" rid="CR56">2005</xref>). SARS-CoV caused a global epidemic from November 2002 to 2003; about 8422 people were infected in 32 countries, 916 persons died, and the fatality rate was 10&#x02013;15%. Analysis of the full sequence of SARS-CoV, which is about 29.7&#x000a0;kb in length, reveals that it is a large, single-stranded, positive-sense RNA virus (Keum and Jeong <xref ref-type="bibr" rid="CR49">2012</xref>).</p><p id="Par6">In 2013, MERS-CoV also triggered an epidemic in the Middle East and a major outbreak in South Korea occurred in May&#x02013;June 2015 (Kim et al. <xref ref-type="bibr" rid="CR54">2017a</xref>). With a case-fatality rate of 35.5%, MERS-CoV is heavily endemic in dromedary camels and causes lower respiratory tract infections in humans (Kim et al. <xref ref-type="bibr" rid="CR54">2017a</xref>). Although the SARS-CoV epidemic had been under control for years, Wang et al. (<xref ref-type="bibr" rid="CR112">2017</xref>) warned that re-emergence of this threatening infection posed a possible global risk as potentially new strains of SARS-CoV would be more dangerous than the previous ones.</p><p id="Par7">Toward the end of 2019 and the beginning of 2020, multiple human cases of a new viral infection were reportedly linked to the Huanan Seafood Wholesale &#x0201c;wet&#x0201d; Market (South China Seafood City Food Market) in Wuhan, China (Li et al. <xref ref-type="bibr" rid="CR67">2020</xref>; Zhang et al. <xref ref-type="bibr" rid="CR127">2020</xref>). On 7 January 2020, the new virus was identified as a novel coronavirus and officially named by the World Health Organization as 2019-nCoV (Li et al. <xref ref-type="bibr" rid="CR67">2020</xref>). On 20 January 2020, the National Health Commission of China confirmed the human-to-human transmission of 2019-nCoV with its presenting common symptoms such as fever, tiredness, dry cough, shortness of breath, and pneumonia (Elfiky <xref ref-type="bibr" rid="CR30">2020</xref>), and less common signs as diarrhea, conjunctivitis, headache, loss of taste or smell, and rash on skin or discoloration of fingers and toes. The World Health Organization also recognized 2019-nCoV as the causative agent of the coronavirus disease 2019 (COVID-19). The 2019-nCoV was later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses, Coronaviridae Study Group (Ling <xref ref-type="bibr" rid="CR72">2020</xref>).</p><p id="Par8">A phylogenetic analysis found a bat origin for the SARS-CoV-2 (Lu et al. <xref ref-type="bibr" rid="CR77">2020</xref>; Wan et al. <xref ref-type="bibr" rid="CR110">2020</xref>). Yang et al. (<xref ref-type="bibr" rid="CR124">2020</xref>) reported that SARS-CoV-2, formerly known as 2019-nCoV, the causative pathogen of COVID-19, had rapidly spread across China and around the world, causing an outbreak of acute infectious pneumonia. The spread of SARS-CoV-2, a new highly contagious and lethal strain of HCoVs, has now caused a global pandemic (Remuzzi and Remuzzi <xref ref-type="bibr" rid="CR96">2020</xref>). In the morning of 7 September 2020, Johns Hopkins University reported that there were over 26,994,442 total confirmed cases and 880,994 deaths globally; over 6,189,488 cases and 187,541 deaths were in the United States of America (USA). COVID-19 has spread more rapidly due to increased global travel and adaptation of SARS-CoV-2 in every environment (Vellingiri et al. <xref ref-type="bibr" rid="CR109">2020</xref>).</p><p id="Par9">Currently, the seven identified human coronaviruses (HCoVs) are SARS-CoV-2, MERS-CoV, SARS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 strains (Andersen et al. <xref ref-type="bibr" rid="CR1">2020</xref>). Molecular evolutionary analysis shows that all HCoVs originate in animals; SARS-CoV, MERS-CoV, HCoV-NL63, and HCoV-229E are derived from bats; HCoV-OC43 and HCoV-HKU1 are sourced from rodents (Forni et al. <xref ref-type="bibr" rid="CR34">2017</xref>). The 229E and NL63 strains of HCoVs belong to alpha coronaviruses while OC43, HKU1, SARS, MERS, and SARS-CoV-2 belong to beta coronaviruses (Elfiky <xref ref-type="bibr" rid="CR30">2020</xref>). Most people infected with SARS-CoV, MERS-CoV, and SARS-CoV-2 present with severe respiratory distress, and many of the infected succumb to coronavirus infection (Andersen et al. <xref ref-type="bibr" rid="CR1">2020</xref>).</p><p id="Par10">Pillaiyar et al. (<xref ref-type="bibr" rid="CR92">2020</xref>) reviewed recent developments in the discovery and development of synthetic drugs to treat HCoVs. However, these drugs have not achieved extended distribution for clinical application because they have not yet been tested in rigorous randomized controlled clinical trials (Ford et al. <xref ref-type="bibr" rid="CR33">2020</xref>). Zhou et al. (<xref ref-type="bibr" rid="CR135">2020a</xref>, <xref ref-type="bibr" rid="CR137">b</xref>) reported that there were no effective drugs targeting SARS-CoV-2. Yang et al. (<xref ref-type="bibr" rid="CR124">2020</xref>) also stated no efficacious and safe antiviral drugs or vaccines were available for the treatment of this sudden and lethal disease. Supportive care and non-specific treatment to ameliorate COVID-19 symptoms of the patient are the main options available.</p><p id="Par11">Remdesivir, produced by the company Gilead, shows EC<sub>90</sub> of 1.76&#x000a0;&#x003bc;M against SARS-CoV-2 <italic>in vitro</italic> (Elfiky <xref ref-type="bibr" rid="CR30">2020</xref>). On 1 May 2020, remdesivir was granted approval by the US Food and Drug Administration for emergency use in the treatment of COVID-19 patients. An inhibitor of the enzyme RNA-dependent RNA polymerase (RdRp) involved in HCoV replication, the drug reduced mortality from 11 to 8% and duration of symptoms from 15 to 11&#x000a0;days. However, in comparison with the placebo, remdesivir&#x02019;s reduction of patient mortality was not significantly different.</p><p id="Par12">Due to the absence of conventional therapies, Yang et al. (<xref ref-type="bibr" rid="CR124">2020</xref>) reported that more than 85% of SARS-CoV-2-infected patients in China were treated with traditional Chinese medicine (TCM). During the 2002 to 2003 outbreak, TCM was also used as a supplementary treatment of severe laboratory-confirmed conditions of SARS (Hsu et al. <xref ref-type="bibr" rid="CR41">2006a</xref>). Along this trajectory, the aim of the current review is to provide an update on the bioactivity functions of medicinal plants and other natural products that have previously been used to treat coronaviruses. In the short term, knowledge of these natural products may be significant in the relief of COVID-19 symptoms. In the long term, natural products that alleviate COVID-19 symptoms may be used in the search for novel drugs against SARS-CoV-2. In the face of current challenges to the treatment of COVID-19, data presented in this review may help to reimagine a new future where natural products are the new frontier for more efficacious and low-cost SARS-CoV-2 inhibitors. The goal is to create a strong bioprospecting pipeline from which pharmaceutical companies can advance the discovery and repurposing of COVID-19 drugs from current medicinal plants and other natural products.</p><p id="Par13">To prevent author bias, this review was carried out using a comprehensive and systematic data mining approach similar to that used by Chinsembu (<xref ref-type="bibr" rid="CR18">2019</xref>). To obtain pertinent literature, the key words &#x0201c;SARS&#x0201d; and &#x0201c;medicinal plants&#x0201d; were concomitantly searched in Google Scholar, Elsevier&#x02019;s pay-to-view service Science Direct, Scopus, Scielo, and PubMed Central, the US National Library of Medicine&#x02019;s digital archive of biomedical and life sciences journal literature. Literature sources included peer-reviewed journal articles and refereed books. Medicinal plants, mushrooms, algae, and sponges with anti-SARS activity were included. Wherever possible, active compounds and anti-SARS profiles mainly half maximal inhibitory concentration (IC<sub>50</sub>) and effective concentration (EC<sub>50</sub>) were recorded. Inclusion criteria included plants, fungi, and marine organisms, namely algae and sponges. Exclusion criteria included animal products. Countries reported in the review were those where primary data were collected; hence, geographical scope was not deliberately selected. The International Plant Names Index (<ext-link ext-link-type="uri" xlink:href="http://www.ipni.org">http://www.ipni.org</ext-link>) and The Plant List (<ext-link ext-link-type="uri" xlink:href="http://www.theplantlist.org">http://www.theplantlist.org</ext-link>) were used to verify names of plant species.</p></sec><sec id="Sec2"><title>Discussion</title><sec id="Sec3"><title>Entry Inhibitors</title><p id="Par14">The spike protein, a type I membrane-bound protein, is essential for SARS-CoV attachment to the host cell receptor angiotensin-converting enzyme 2 (ACE2). In general, SARS-CoV entry starts with the attachment of the virus to its specific receptor ACE2 on the host cell surface (Keyaerts et al. <xref ref-type="bibr" rid="CR50">2007</xref>). Binding of ACE2 then induces the viral envelope protein to undergo conformational changes that mediate fusion between SARS-CoV and host cell membranes. The spike protein is responsible for these two steps in the coronavirus entry process (Keyaerts et al. <xref ref-type="bibr" rid="CR50">2007</xref>). A member of the C-type lectin superfamily, dendritic cell (DC)-specific ICAM-grabbing non-intergrin (DC-SIGN), a molecule designated as CD209, binds to surface proteins of SARS-CoV, consequently facilitating viral entry (Liu et al. <xref ref-type="bibr" rid="CR75">2015</xref>). SARS-CoV spike protein contains a number of <italic>N</italic>-linked glycosylation sites that modulate binding to the DC-SIGN receptor on DC (Zhang et al. <xref ref-type="bibr" rid="CR132">2007</xref>). SARS-CoV binding to DC-SIGN is required for DC infection and target cell <italic>trans</italic>-infection. DC-SIGN plays an important role in mediating DC adhesion and internalization of SARS-CoV.</p><p id="Par15">Antiviral agents from plants generally block virus entry and membrane fusion (Hsieh et al. <xref ref-type="bibr" rid="CR40">2004</xref>). De Clercq (<xref ref-type="bibr" rid="CR25">2005</xref>) suggested that it was feasible to develop SARS-CoV fusion inhibitors analogous to enfuvirtide, a linear 36-amino acid synthetic peptide marketed under the trade name Fuzeon, an approved anti-HIV drug that inhibits the entry of the virus into cells. SARS-CoV entry inhibitors fall into several categories. The first group consists of inhibitors that bind to the ACE2 receptor, the second class comprises entry inhibitors that bind to the virus and prevent it from interacting with its receptors, and the third set of inhibitors can obstruct the conformational changes thus thwarting SARS-CoV fusion with the target cells (Keyaerts et al. <xref ref-type="bibr" rid="CR50">2007</xref>). An effective inhibitor of SARS-CoV, the medicinal basidiomycete <italic>Ganoderma lucidum</italic> (Curtis) Karst. contains ganoderic acid F, a lanostane triterpene that acts as an inhibitor of ACE2 receptor (IC<sub>50</sub> 4.7&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup>&#x000a0;M) (Morigiwa et al. <xref ref-type="bibr" rid="CR84">1986</xref>).</p></sec><sec id="Sec4"><title>Lectins as Biologics</title><p id="Par16">Lee (<xref ref-type="bibr" rid="CR62">2019</xref>) asserts that lectins have emerged as a new class of antiviral biologic drugs or biologics by taking advantage of a unique glycosylation pattern only found on the surface of viruses. Lectins, a group of proteins with carbohydrate recognition activity, recognize the SARS-CoV spike protein (Liu et al. <xref ref-type="bibr" rid="CR75">2015</xref>). Keyaerts et al. (<xref ref-type="bibr" rid="CR50">2007</xref>) found prominent anti-SARS-CoV activity among mannose-specific plant lectins. One of the most potent lectins against the SARS-CoV-induced cytopathicity is the mannose-specific plant lectin isolated from leek (<italic>Allium porrum</italic> L.) with an EC<sub>50</sub> of 0.45&#x000a0;&#x003bc;g/ml and a selectivity index of &#x0003e;&#x02009;222. The <italic>N</italic>-acetyl glucosamine-specific lectins isolated from the stinging nettle (<italic>Urtica dioica</italic> L.) and from the tobacco plant (<italic>Nicotiana tabacum</italic> L.) were also markedly active against the SARS-CoV with a selectivity index of &#x0003e;&#x02009;77 and &#x0003e;&#x02009;59, respectively (Kumaki et al. <xref ref-type="bibr" rid="CR58">2011</xref>). A mannose-specific lectin (agglutinin) of <italic>Hippeastrum striatum</italic> (Lam.) H.E.Moore prevented the penetration of SARS-CoV into Vero E6 cells (EC<sub>50</sub> 2.5&#x000a0;&#x003bc;g/ml at 4&#x000a0;&#x000b0;C) (Keyaerts et al. <xref ref-type="bibr" rid="CR50">2007</xref>). SARS-CoV spike protein contains 12 <italic>N</italic>-glycosylation sites and the sugars attached to four of these <italic>N-</italic>glycosylation sites have been identified (Zhou et al. <xref ref-type="bibr" rid="CR138">2010</xref>). Two of the four sugars were found to be high-mannose-type glycans and the other two showed complex glycan structures (Zhang et al. <xref ref-type="bibr" rid="CR128">2005</xref>). The potent anti-SARS-CoV activity of mannose-specific plant lectins is therefore attributable to the presence of high-mannose-type glycans in the SARS-CoV spike protein (Keyaerts et al. <xref ref-type="bibr" rid="CR50">2007</xref>; Zhou et al. <xref ref-type="bibr" rid="CR138">2010</xref>).</p><p id="Par17">Many lectins from algae have antiviral activity. A highly potent broad-spectrum antiviral, griffithsin is a 121-amino acid red alga-derived lectin that binds to the terminal mannose residues of the asparagine(<italic>N</italic>)-linked Man 5&#x02013;9 GlcNAc2 structures found on the envelope of SARS-CoV (Lee <xref ref-type="bibr" rid="CR62">2019</xref>). Initially identified as an anti-HIV-1 agent with EC<sub>50</sub> of 0.43&#x02013;0.98&#x000a0;nM, griffithsin isolated from the aqueous extract of the red algae <italic>Griffithsia corallinoides</italic> (L.) Trevisan found off the eastern shore of Chatham Island, New Zealand, is a 12.7-kDa lectin that also inhibits SARS-CoV (EC<sub>50</sub> 0.048&#x02013;960&#x000a0;nM), various avian CoV subtypes (EC<sub>50</sub> 0.032&#x02013;0.57&#x000a0;nM), bovine CoV (EC<sub>50</sub> 0.057&#x000a0;nM), puffinosis CoV (EC<sub>50</sub> 0.57&#x000a0;nM), and HCoV mutants with EC<sub>50</sub> of 0.16&#x000a0;nM (Mitchell et al. <xref ref-type="bibr" rid="CR82">2017</xref>).</p></sec><sec id="Sec5"><title>Protease Inhibitors</title><p id="Par18">Some viruses such as Ebola and SARS-COV use cathepsins, a family of proteases, to infect host cells (Huang et al. <xref ref-type="bibr" rid="CR43">2006</xref>). Inhibitors of cathepsin L prevent entry of SARS-CoV into target cells (Simmons et al. <xref ref-type="bibr" rid="CR106">2005</xref>). Unfortunately, many cathepsin inhibitors are non-selective (Zhou et al. <xref ref-type="bibr" rid="CR134">2016</xref>). Leupeptin (<bold>1</bold>), also known as <italic>N</italic>-acetyl-<sc>l</sc>-leucyl-<sc>l</sc>-leucyl-<sc>l</sc>-argininal, is protease inhibitor produced by actinomycetes and isolated from a strain of <italic>Streptomyces exfoliatus</italic> (Waksman and Curtis) Waksman and Henrici, which can inhibit cysteine, serine, and threonine peptidases. Simmons et al. (<xref ref-type="bibr" rid="CR106">2005</xref>) showed that inhibitors of proteases such as leupeptin act as potent inhibitors of SARS-CoV entry into host cells. SARS-CoV spike protein-driven virus-cell fusion is inhibited by <bold>1</bold> (Simmons et al. <xref ref-type="bibr" rid="CR105">2011</xref>), which exhibited a dose-dependent inhibition of SARS-CoV infection (Zhou et al. <xref ref-type="bibr" rid="CR136">2011</xref>) (IC<sub>95</sub> 15.2&#x000a0;&#x003bc;M). This inhibition is the result of an absolute requirement in cell lines for endosomal processing of the SARS-CoV spike protein by cathepsin L during entry into the target cell (Simmons et al. <xref ref-type="bibr" rid="CR105">2011</xref>). The oligopeptide antipain (<bold>2</bold>), an inhibitor of trypsin and papain, isolated from actinomycetes inhibited SARS-COV entry into host cells (Simmons et al. <xref ref-type="bibr" rid="CR106">2005</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figb_HTML" id="MO2"/></sec><sec id="Sec6"><title>Anthraquinone Derivatives</title><p id="Par19">Emodin (<bold>3</bold>) is a naturally occurring anthraquinone derivative and an active ingredient of medicinal plants including <italic>Rheum palmatum</italic> L., <italic>Rheum tanguticum</italic> Maxim. ex Balf., <italic>Polygonum cuspidatum</italic> Siebold &#x00026; Zucc., <italic>Polygonum multiflorum</italic> Thunb., <italic>Aloe vera</italic> (L.) Burm.f., <italic>Senna obtusifolia</italic> (L.) H.S.Irwin &#x00026; Barneby (Dong et al. <xref ref-type="bibr" rid="CR28">2016</xref>; Zhou et al., <xref ref-type="bibr" rid="CR135">2020a</xref>, <xref ref-type="bibr" rid="CR137">b</xref>), and <italic>Cassia tora</italic> L. Emodin inhibited SARS-CoV via the blockage of viral entry by binding to the spike proteins and interfering with SARS-CoV 3CL<sup>pro</sup> activity (Hyun et al. <xref ref-type="bibr" rid="CR45">2009</xref>). In assays involving SARS-CoV and HCoV-OC43, emodin in a dose-dependent manner significantly blocked the interaction between the SARS-CoV spike protein and ACE2 (a functional SARS-CoV receptor), inhibited the 3a ion channel (<italic>K</italic><sub>1/2</sub> value of about 20&#x000a0;&#x003bc;M), and stopped new coronavirus release (Dong et al. <xref ref-type="bibr" rid="CR28">2016</xref>; Ho et al. <xref ref-type="bibr" rid="CR39">2007</xref>). SARS-CoV-2 spike protein directly binds to the host cell surface ACE2 receptor facilitating virus entry and replication (Zhang et al. <xref ref-type="bibr" rid="CR127">2020</xref>). Corollary, emodin can be considered a potential lead therapeutic agent in the treatment of SARS-CoV-2 infection. Experimental data now suggest that combining emodin and the drug toremifene, a first-generation non-steroidal selective estrogen receptor modulator for the treatment of metastatic breast cancer, provides a potential therapeutic approach for SARS-CoV-2 (Zhou et al., <xref ref-type="bibr" rid="CR135">2020a</xref>, <xref ref-type="bibr" rid="CR137">b</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figc_HTML" id="MO3"/></sec><sec id="Sec7"><title>Triterpene and Their Glycosides</title><p id="Par20">Terpenoids isolated from medicinal plants have attracted attention because many of them exhibit specific <italic>in vitro</italic> antiviral effect against SARS-CoV (Wen et al. <xref ref-type="bibr" rid="CR116">2007</xref>). Triterpenoids inhibit the entry of Ebola, Marburg, HIV, and influenza A viruses with distinct structure-activity relationships (Si et al. <xref ref-type="bibr" rid="CR104">2018</xref>). These natural agents modulate a broad range of virus-host fusion functions via wrapping the heptad repeat 2 domain prevalent in viral envelopes. <italic>Euphorbia neriifolia</italic> L. produces 22 triterpenoids with stronger activity against HCoVs than actinomycin D (Chang et al. <xref ref-type="bibr" rid="CR7">2012</xref>).</p><p id="Par21">Saikosaponins represent a group of oleanane derivatives, usually as glucosides, found in medicinal plants in the genera <italic>Bupleurum</italic> L., <italic>Heteromorpha</italic> Cham. &#x00026; Schltdl., and <italic>Scrophularia</italic> L. (Cheng et al. <xref ref-type="bibr" rid="CR14">2006</xref>). Saikosaponins A, B<sub>2</sub>, C, and D demonstrated anti-HCoV-229E activity at concentrations of 0.25&#x02013;25&#x000a0;&#x003bc;M, with the strongest activity being noted for saikosaponin B<sub>2</sub> (<bold>4</bold>) (IC<sub>50</sub> 1.7&#x02009;&#x000b1;&#x02009;0.1&#x000a0;&#x003bc;M) (Cheng et al. <xref ref-type="bibr" rid="CR14">2006</xref>). Since saikosaponin B<sub>2</sub> blocks HCoV-229E attachment and penetration, it could be a novel lead for the development of a potential chemo-preventive agent for SARS-CoV infection (Cheng et al. <xref ref-type="bibr" rid="CR14">2006</xref>). Yang et al. (<xref ref-type="bibr" rid="CR124">2020</xref>) reported that saikosaponins and glycyrrhizin from <italic>Toona sinensis</italic> (Juss.) M.Roem. had potent anti-SARS-CoV effects by inhibition of viral cellular entry, adsorption, and penetration.</p><graphic position="anchor" xlink:href="43450_2020_104_Figd_HTML" id="MO4"/><p id="Par22">The licorice plant, <italic>Glycyrrhiza glabra</italic> L., was reported to have specific anti-SARS effects (Polansky and Lori <xref ref-type="bibr" rid="CR93">2020</xref>). Constituents of licorice include triterpenoids such as glycyrrhizin or glycyrrhizic acid (<bold>5</bold>). Glycyrrhizin (<bold>5</bold>) exerted very high antiviral activity and <italic>in vitro</italic> inhibition of SARS-CoV (EC<sub>50</sub> 300&#x000a0;&#x003bc;g/ml) (Cinatl et al. <xref ref-type="bibr" rid="CR23">2003</xref>). Glycyrrhizin and its derivatives inhibited SARS-CoV replication <italic>in vitro</italic> (Baltina et al. <xref ref-type="bibr" rid="CR4">2015</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Fige_HTML" id="MO5"/><p id="Par23">Ryu et al. (<xref ref-type="bibr" rid="CR100">2010a</xref>) reported that 95% methanolic extracts of the bark of <italic>Tripterygium regelii</italic> Sprague &#x00026; Takeda remarkably inhibited SARS-CoV 3CL<sup>pro</sup> activity (&#x0003e;&#x02009;70% inhibition at 30&#x000a0;&#x003bc;g/ml) (Ryu et al. <xref ref-type="bibr" rid="CR100">2010a</xref>). The active compounds of <italic>T. regelii</italic> are four quinone-methide triterpenoid derivatives: celastrol, pristimerin, tingenone, and iguesterin (<bold>6</bold>) with IC<sub>50</sub> values of 10.3, 5.5, 9.9, and 2.6&#x000a0;&#x003bc;M, respectively, against SARS-CoV 3CL<sup>pro</sup> (Ryu et al. <xref ref-type="bibr" rid="CR100">2010a</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figf_HTML" id="MO6"/><p id="Par24">The seeds of <italic>Aesculus turbinata</italic> Blume, a medicinal plant found in China, Japan, and South Korea, contain a natural saponins called escins, constituents with strong virucidal effects against SARS-CoV (EC<sub>50</sub> of 6&#x000a0;&#x003bc;M, selectivity index value of 2.5) (Kim et al. <xref ref-type="bibr" rid="CR55">2017b</xref>; Salinas et al. <xref ref-type="bibr" rid="CR101">2019</xref>). Betulin and betulinic acid, the main antiviral components of the <italic>Betula</italic> L. plants, inhibit HIV fusion and one of the steps in HIV maturation (Chinsembu <xref ref-type="bibr" rid="CR16">2016a</xref>). A methanolic extract of <italic>Betula papyrifera</italic> Marshall exerted antiviral activity against bovine coronavirus (Rastogi et al. <xref ref-type="bibr" rid="CR95">2015</xref>).</p></sec><sec id="Sec8"><title>Polyphenols and Miscellaneous Aromatic Compounds</title><p id="Par25">Many natural polyphenols, with antioxidant properties, possess antiviral activity and some of them, for example, myricetin (<bold>7</bold>), an inhibitor of coronavirus helicase nsP13 (IC<sub>50</sub> value of 2.71&#x000a0;&#x003bc;M), are already being used against coronaviruses (Semwal et al. <xref ref-type="bibr" rid="CR103">2016</xref>; Yu et al. <xref ref-type="bibr" rid="CR126">2012</xref>). Naturally occurring flavonoids such as quercetin, naringin, hesperetin, and catechin, the most abundant polyphenols in the human diet, are usually found in fruit and vegetables as glycosides and sometimes as acylglycosides. Luteolin and quercetin can interfere with adsorption of the virus to its host cells. It was hypothesized that specific flavonoids, such as quercetin, hesperetin, and myricetin (<bold>7</bold>) and their glycosylated derivatives, may play an effective role in inhibiting SARS-CoV entry into host cells, specifically by binding with high affinity to the spike protein, helicase, and protease sites on the ACE receptor (Ngwa et al. <xref ref-type="bibr" rid="CR86">2020</xref>), in addition to acting against fatty acid synthase (Wen et al., <xref ref-type="bibr" rid="CR117">2011</xref>). Extracted from TCM herbal formulae used to treat SARS, the following active polyphenols inhibited various steps during SARS-CoV entry and replication: baicalin, emodin, epigallocatechin, gallate, gallocatechin gallate, herbacetin, isobavaschalcone, kaempferol derivatives, luteolin, myricetin, quercetin, 3-&#x003b2;-<sc>d</sc>-glucoside, rhoifolin, pectolinarin, scutellarein, and tetra-<italic>O</italic>-galloyl-&#x003b2;-<sc>d</sc>-glucose (Yang et al. <xref ref-type="bibr" rid="CR124">2020</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figg_HTML" id="MO7"/><p id="Par26">Quercetin (<bold>8</bold>) is an aglycone present at high concentration in onions. This compound has virucidal activity against enveloped viruses such as mengovirus, herpes simplex, parainfluenza type 3, pseudorabies, respiratory syncytial, and Sindbis viruses (Choi et al. <xref ref-type="bibr" rid="CR21">2009</xref>). Quercetin is able to inhibit H<sup>+</sup>-ATPase of lysosomal membrane and thus prevents virus coat removal and blocks viral replication and competitively inhibits SARS-CoV 3CL<sup>pro</sup> with IC<sub>50</sub> of 42.79&#x02009;&#x000b1;&#x02009;4.97&#x000a0;&#x003bc;M (Chen et al. <xref ref-type="bibr" rid="CR11">2006</xref>).</p><p id="Par27"><italic>Torreya nucifera</italic> (L.) Siebold &#x00026; Zucc. is a traditional medicinal plant in Asia. The ethanol leaf extract of <italic>T. nucifera</italic> exerts good SARS-CoV 3CL<sup>pro</sup> inhibitory activity (62% at 100&#x000a0;&#x003bc;g/ml) (Ryu et al. <xref ref-type="bibr" rid="CR99">2010b</xref>). Following the bioactivity-guided fractionation of <italic>T. nucifera</italic>, the biflavone amentoflavone (<bold>9</bold>) showed the most potent SARS-CoV 3CL<sup>pro</sup> inhibitory effect with IC<sub>50</sub> of 8.3&#x000a0;&#x003bc;M (Ryu et al. <xref ref-type="bibr" rid="CR99">2010b</xref>). Apigenin, luteolin, and quercetin inhibited SARS-CoV 3CL<sup>pro</sup> activity with IC<sub>50</sub> values of 280.8, 20.2, and 23.8&#x000a0;&#x003bc;M, respectively (Ryu et al. <xref ref-type="bibr" rid="CR99">2010b</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figh_HTML" id="MO8"/><p id="Par28">Zhong et al. (<xref ref-type="bibr" rid="CR133">2013</xref>) found that Jinchai, a capsule of TCM consisting of plants such as <italic>Lonicera japonica</italic> Thunb., <italic>Bupleurum chinense</italic> DC., <italic>Astragalus membranaceus</italic> (Fisch.) Bunge, and <italic>Codonopsis pilosula</italic> subsp. <italic>tangshen</italic> (Oliv.) D.Y.Hong inhibited SARS-CoV. Jinchai blocks SARS-CoV infection by weakening adsorption of viruses to cells and reduces the ability of SARS-CoV to infect surrounding tissues (Zhong et al. <xref ref-type="bibr" rid="CR133">2013</xref>). The main active constituents of Jinchai are chlorogenic acid and baicalin (<bold>10</bold>) whose EC<sub>50</sub> (&#x003bc;g/ml) at 48&#x000a0;h was 12.5 to 25, EC<sub>50</sub> (&#x003bc;g/ml) at 72&#x000a0;h was 25 to 50, CC<sub>50</sub> (&#x003bc;g/ml) was &#x0003e;&#x02009;100, and SI calculated as CC<sub>50</sub>/EC<sub>50</sub> at 48&#x000a0;h was &#x0003e;&#x02009;4 to 8 (Chen et al. <xref ref-type="bibr" rid="CR10">2004</xref>). <italic>Camellia sinensis</italic> (L.) Kuntze (black tea) polyphenol epigallocatechin gallate (EGCG) inhibited bovine coronavirus propagation; EGCG interfered with the adsorption of bovine coronavirus to Madin-Darby bovine kidney cells (Bansal et al. <xref ref-type="bibr" rid="CR5">2013</xref>). Although <italic>Sanguisorba officinalis</italic> L. extract inhibits HIV-1 infection by binding to the viral envelope and blocking entry of the virus, it did not inhibit SARS-CoV entry (Liang et al. <xref ref-type="bibr" rid="CR69">2013</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figi_HTML" id="MO9"/><p id="Par29">In oriental herbal medicine, the bark of cinnamon plant <italic>Cinnamomum cassia</italic> (L.) J. Presl has been used as a spice, infusion, and prime component of herbal remedies for common cold, gastrointestinal infections, cancer, chronic cardiovascular disease, and gynecological disorders. Zhuang et al. (<xref ref-type="bibr" rid="CR140">2009</xref>) found that cinnamon bark extract has anti-RNA viral effects. The cinnamon extract inhibited wild-type SARS-CoV infection <italic>in vitro</italic> with an IC<sub>50</sub> of 43&#x000a0;&#x003bc;M; and the proposed mechanism of action for cinnamon bark extract was blocking cell entry via endocytosis (Polansky and Lori <xref ref-type="bibr" rid="CR93">2020</xref>). Whereas the antiviral, anti-bacterial, and anti-cancer effects were attributable to essential oils such as cinnamaldehyde (<bold>11</bold>), the anti-inflammatory actions of cinnamon water extract were due to the presence of polyphenols such as flavonoids and tannins. Molecular docking studies show that <bold>11</bold> may block the attachment of SARC-CoV-2, though detailed <italic>in vitro</italic> and <italic>in vivo</italic> studies are required to confirm its efficacy (Asif et al. <xref ref-type="bibr" rid="CR3">2020</xref>). Compound <bold>11</bold> had the lowest electronegativity value among the phytochemicals with a score of &#x02212;&#x02009;4.34; binding affinity in kilocalorie per mole was &#x02212;&#x02009;5 (Asif et al. <xref ref-type="bibr" rid="CR3">2020</xref>; Kulkarni et al. <xref ref-type="bibr" rid="CR57">2020</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figj_HTML" id="MO10"/><p id="Par30">Stilbene derivatives displayed antiviral activities against SARS-CoV (Li et al. <xref ref-type="bibr" rid="CR66">2006</xref>). The stilbenoid resveratrol (<bold>12</bold>) exists widely in different plants including grape <italic>Vitis vinifera</italic> L., <italic>Polygonum cuspidatum</italic>, and cranberry <italic>Vaccinium macrocarpon</italic> Aiton (Lin et al. <xref ref-type="bibr" rid="CR71">2017</xref>). Resveratrol inhibits various viral infections, including the inhibition of HIV and SARS-CoV replication (Li et al. <xref ref-type="bibr" rid="CR66">2006</xref>). Compound <bold>12</bold> was a potent <italic>in vitro</italic> inhibitor of SARS-CoV (at &#x02264;&#x02009;0.5&#x000a0;mg/ml) and MERS-CoV, at &#x02264;&#x02009;62.5&#x000a0;&#x003bc;M within 24&#x000a0;h of infection (Li et al. <xref ref-type="bibr" rid="CR66">2006</xref>; Lin et al. <xref ref-type="bibr" rid="CR71">2017</xref>). It was predicted that resveratrol (<bold>12</bold>) could be a potential agent against new HCoVs in the near future (Lin et al. <xref ref-type="bibr" rid="CR71">2017</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figk_HTML" id="MO11"/></sec></sec><sec id="Sec9"><title>General Inhibitors of Replication</title><p id="Par31">Polysaccharides isolated from TCM herb <italic>Astragalus mongholicus</italic> Bunge have been widely used to boost immunity against viruses. A study by Zhang et al. (<xref ref-type="bibr" rid="CR129">2018</xref>) showed that supplementation with <italic>A. mongholicus</italic> polysaccharides can inhibit the replication of avian coronaviruses. Extracts of <italic>Acanthopanax gracilistylus</italic> var. <italic>trifoliolatus</italic> C.B. Shang, the root of <italic>Sophora flavescens</italic> Aiton, and the dried root of <italic>Sanguisorba officinalis</italic> and <italic>Torilis elata</italic> Spreng. reduced the <italic>in vitro</italic> replication of SARS-CoV more potently than the ribavirin drug control (Kim et al. <xref ref-type="bibr" rid="CR52">2010</xref>).</p><p id="Par32"><italic>Cimicifuga racemosa</italic> (L.) Nutt., <italic>Melia azedarach</italic> L., <italic>Coptis chinensis</italic> Franch., <italic>Phellodendron chinense</italic> C.K.Schneid., and <italic>Sophora tonkinensis</italic> var. <italic>polyphylla</italic> X.C.Huang &#x00026; Z.C.Zhou decreased mouse hepatitis virus A59 (MHV-A59) production and intracellular viral RNA and protein expression with EC<sub>50</sub> values ranging from 2 to 27.5&#x000a0;&#x003bc;g/ml (Kim et al. <xref ref-type="bibr" rid="CR53">2008</xref>). <italic>Cimicifuga racemosa</italic>, <italic>M. azedarach</italic>, <italic>C. chinensis</italic>, <italic>P. chinense</italic>, and <italic>S. tonkinensis</italic> were good candidates for the treatment of coronaviral infections in both humans and animals (Kim et al. <xref ref-type="bibr" rid="CR53">2008</xref>). The underlying antiviral mechanism was most likely due to the inhibition of RNA-dependent RNA polymerase or proteases that are crucial for coronavirus RNA replication. <italic>Melia azedarach</italic> and <italic>C. chinensis</italic> may also affect virus assembly or release.</p><p id="Par33">Silvestrol (<bold>13</bold>), a natural cyclopenta[b]benzofuran, isolated from the fruits and twigs of <italic>Aglaia foveolata</italic> Pannell, at 0.6&#x02013;2&#x000a0;&#x003bc;M, inhibited cap-dependent viral mRNA translation of HCoV-229E with an IC<sub>50</sub> of 40&#x000a0;nM (M&#x000fc;ller et al. <xref ref-type="bibr" rid="CR85">2018</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figl_HTML" id="MO12"/><p id="Par34">Ouabain (<bold>14</bold>), also known as g-strophanthin, is a toxic cardiac glycoside that was traditionally used as an arrow poison for both hunting and warfare in eastern Africa. However, this substance, in lower doses, can be used medically to treat hypotension and some arrhythmias. In addition, ouabain diminishes SARS-CoV titers and the number of SARS-CoV RNA copies at 0&#x02013;3000&#x000a0;nM (Yang et al. <xref ref-type="bibr" rid="CR123">2018</xref>). Wu et al. (<xref ref-type="bibr" rid="CR119">2020</xref>) described drug names, chemical structures, pharmacological functions, and sources of 20 potential RdRp inhibitors from an in-house natural product database. Their results were based on computer virtual screening because no <italic>in vitro</italic> and <italic>in vivo</italic> experiments were conducted.</p><graphic position="anchor" xlink:href="43450_2020_104_Figm_HTML" id="MO13"/><p id="Par35">Andrographolide has been studied for its effects on cell signaling, immunomodulation, and stroke. Using computational approaches, Enmozhi et al. (<xref ref-type="bibr" rid="CR32">2020</xref>) showed that andrographolide (<bold>15</bold>), an extremelly bitter labdane diterpenoid isolated from <italic>Andrographis paniculata</italic> (Burm.f.) Wall. ex Nees, docked successfully in the binding site of SARS-CoV-2 M<sup>pro</sup>. The molecule obeys Lipinski&#x02019;s rule making it a promising compound to treat COVID-19 (Enmozhi et al. <xref ref-type="bibr" rid="CR32">2020</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Fign_HTML" id="MO14"/><p id="Par36">Omacetaxine mepesuccinate (trade names Synribo), formerly named as homoharringtonine (<bold>16</bold>), is a plant alkaloid derived from <italic>Cephalotaxus fortunei</italic> Hook that was approved by the US FDA in October 2012 for the treatment of chronic myeloid leukemia in adults. Homoharringtonine has been reported to exhibit potent inhibitory activity against coronaviruses, namely porcine epidemic diarrhea virus, murine hepatitis virus (Dong et al. <xref ref-type="bibr" rid="CR27">2018</xref>; Andersen et al. <xref ref-type="bibr" rid="CR2">2019</xref>), and SARS-CoV-2 with EC<sub>50</sub> at 2.10&#x000a0;&#x003bc;M (Choy et al. <xref ref-type="bibr" rid="CR22">2020</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figo_HTML" id="MO15"/><p id="Par37">Tylophorine (<bold>17</bold>), a phenanthraindolizidine alkaloid, has anti-HCoV activity in the nanomolar concentrations, up to 1000&#x000a0;nM (Islam et al. <xref ref-type="bibr" rid="CR47">2020</xref>). Tylophorine derivatives, including naturally occurring and synthetic phenanthroindolizidines and phenanthroquinolizidines, have been identified as potent <italic>in vitro</italic> inhibitors of enteropathogenic coronavirus transmissible gastroenteritis virus (TGEV). This class of potent compounds showed EC<sub>50</sub> values ranging from 8 to 1468&#x000a0;nM as determined by immunofluorescent assay of the expression of TGEV spike and nucleocapsid proteins and by real-time qRT-PCR analysis of viral yields. Tylophorine compounds could be novel leads for further drug development on their own or as templates for drug design (Islam et al. <xref ref-type="bibr" rid="CR47">2020</xref>). Tylophorine and related alkaloids, isolated from <italic>Tylophora indica</italic> Merr., inhibit TGEV replication for anti-coronavirus activity and suppress nitric oxide production in RAW264.7 cells, a measure of antiinflammation (Lee et al., <xref ref-type="bibr" rid="CR63">2012a</xref>, <xref ref-type="bibr" rid="CR64">b</xref>). Additionally, a pharmacokinetic study demonstrated high and comparable oral bioavailabilities of tylophorine (65.7%) in rats (Lee et al., <xref ref-type="bibr" rid="CR63">2012a</xref>, <xref ref-type="bibr" rid="CR64">b</xref>).</p><graphic position="anchor" xlink:href="43450_2020_104_Figp_HTML" id="MO16"/></sec><sec id="Sec10"><title>Inhibitors of Chymotrypsin-Like Protease in SARS-CoV</title><p id="Par38">The chymotrypsin-like protease (3CL<sup>pro</sup>) is vital for SARs-CoV replication and is therefore a promising drug target. The active site of SARS-CoV 3CL<sup>pro</sup> has a catalytic dyad with the sulfur of Cys145 as a nucleophile and the imidazole ring of His41 as a general base (Ryu et al. <xref ref-type="bibr" rid="CR100">2010a</xref>). Also called main protease (M<sup>pro</sup>), the 3CL<sup>pro</sup> of SARS-CoV mediates the proteolytic processing of replicase polypeptides 1a and 1ab into functional proteins; thus, it is an important target for drug development (Lin et al. <xref ref-type="bibr" rid="CR70">2005</xref>). Curcumin inhibits SARS-CoV 3CL<sup>pro</sup> (IC<sub>50</sub> value of 23.5&#x000a0;&#x003bc;M) (Ryu et al. <xref ref-type="bibr" rid="CR100">2010a</xref>). The extracts of <italic>Cibotium barometz</italic> (L.) J.Sm. and <italic>Dioscorea batatas</italic> Decne. also inhibited SARS-CoV 3CL<sup>pro</sup> activity with IC<sub>50</sub> values of 39&#x000a0;&#x003bc;g/ml and 44&#x000a0;&#x003bc;g/ml, respectively (Cuong et al. <xref ref-type="bibr" rid="CR24">2009</xref>; Wen et al. <xref ref-type="bibr" rid="CR117">2011</xref>). Tannic acid, 3-isotheaflavin-3-gallate, and theaflavin-3,3&#x02032;-digallate, three phenolic compounds from black tea, inhibit SARS-CoV 3CL<sup>pro</sup> with IC<sub>50</sub> values of 3, 7, and 9.5&#x000a0;&#x003bc;M, respectively (Chen et al. <xref ref-type="bibr" rid="CR9">2005</xref>).</p><p id="Par39"><italic>Isatis indigotica</italic> Fortune root extracts were frequently used as a remedy during the 2002/2003 SARS outbreak in China. A water extract of <italic>I. indigotica</italic> had anti-SARS-CoV 3CL<sup>pro</sup> activity (Lin et al. <xref ref-type="bibr" rid="CR70">2005</xref>). The root extract of <italic>I. indigotica</italic> contains indigo, indirubin, indican (indoxyl-&#x003b2;-<sc>d</sc>-glucoside), &#x003b2;-sitosterol, &#x003b3;-sitosterol, and sinigrin <bold>(18</bold>). The IC<sub>50</sub> in the cell-free assays was 115&#x000a0;&#x003bc;M for &#x003b2;-sitosterol, 121&#x000a0;&#x003bc;M for sinigrin, and 300&#x000a0;&#x003bc;M for indigo. The cell-based assay indicated that the antioxidant sinigrin (IC<sub>50</sub> 217&#x000a0;&#x003bc;M) was more efficient in blocking the cleavage processing of the 3CL<sup>pro</sup> than indigo (IC<sub>50</sub> 752&#x000a0;&#x003bc;M) and &#x003b2;-sitosterol (IC<sub>50</sub> 1210&#x000a0;&#x003bc;M) (Lin et al. <xref ref-type="bibr" rid="CR70">2005</xref>). Compound <bold>18</bold> is a glucosinolate-type compound also found in some plants of the family Brassicaceae such a Brussels sprouts, broccoli, and the seeds of black mustard (<italic>Brassica nigra</italic> (L.) Andrz.</p><graphic position="anchor" xlink:href="43450_2020_104_Figq_HTML" id="MO17"/></sec><sec id="Sec11"><title>Coronavirus Neutralization and Inactivation</title><p id="Par40">Echinaforce&#x000ae; is a standardized preparation extracted from freshly harvested herb (herba tintura 2580&#x000a0;mg/125 drops) and roots (radix tintura 135&#x000a0;mg/125 drops) of <italic>Echinacea purpurea</italic> (L.) Moench plants (purple coneflower) with a 65% alcoholic solution (Schapowal <xref ref-type="bibr" rid="CR102">2020</xref>). Echinaforce&#x000ae; reduces the infectivity of HCoV-229E in a dose-dependent manner. It inhibits HCoV-229E infection of respiratory epithelial cells (Schapowal <xref ref-type="bibr" rid="CR102">2020</xref>). HCoV-229E was irreversibly inactivated when exposed to Echinaforce&#x000ae; (IC<sub>50</sub> of 3.2&#x000a0;&#x003bc;g/ml) (Schapowal <xref ref-type="bibr" rid="CR102">2020</xref>). Echinaforce&#x000ae; showed a dose-dependent reduction of HCoV 229E infectivity with an IC<sub>50</sub>&#x02009;=&#x02009;9&#x02009;&#x000b1;&#x02009;3&#x000a0;&#x003bc;g/ml (Engler et al. <xref ref-type="bibr" rid="CR31">2017</xref>). Complete neutralization was achieved with 50&#x000a0;&#x003bc;g/ml (Engler et al. <xref ref-type="bibr" rid="CR31">2017</xref>).</p><p id="Par41">Similar inhibition was observed for MERS-CoV when 10&#x000a0;&#x003bc;g/ml of Echinaforce&#x000ae; reduced infectivity by 99.9% and 50&#x000a0;&#x003bc;g/ml of Echinaforce fully blocked infectivity (Engler et al. <xref ref-type="bibr" rid="CR31">2017</xref>). Extracts of <italic>Echinacea purpurea</italic> have been used traditionally in North America for the treatment of various infections and wounds, and they have become very popular herbal medicines globally (Hudson <xref ref-type="bibr" rid="CR44">2012</xref>). Rondanelli et al. (<xref ref-type="bibr" rid="CR97">2018</xref>) found that a combination of <italic>E. purpurea</italic>, vitamin D, vitamin C, and zinc was useful in the treatment of the common cold. Vitamin D supplementation also lessens the risk of COVID-19 infection and deaths (Grant et al. <xref ref-type="bibr" rid="CR36">2020</xref>). <italic>Echinacea angustifolia</italic> DC., <italic>Echinacea pallida</italic> (Nutt.) Nutt., and <italic>Echinacea purpurea</italic> are the most common <italic>Echinacea</italic> Moench species recognized for treating common cold and SARS (Hudson <xref ref-type="bibr" rid="CR44">2012</xref>).</p></sec><sec id="Sec12"><title>Immunomodulatory Agents</title><p id="Par42">Coronavirus infection in humans is characterized by uncontrolled replication of the virus and a prominent pro-inflammatory response (Wong and Yuen <xref ref-type="bibr" rid="CR118">2008</xref>). Still, in the management of coronavirus disease, the role of immunomodulators to decrease excessive inflammation remains elusive (Wong and Yuen <xref ref-type="bibr" rid="CR118">2008</xref>). The immunomodulatory compounds tomentins A&#x02013;E (<bold>19</bold>&#x02013;<bold>23</bold>), geranylated flavonoids, isolated from <italic>Paulownia tomentosa</italic> (Thunb.) Steud. lower the concentration of pro-inflammatory cytokines interleukin-1&#x003b2; and tumor necrosis factor alpha (Cho et al. <xref ref-type="bibr" rid="CR20">2013</xref>). These tomentins could be useful in allaying the multisystem inflammatory syndrome, also known as the cytokine storm, seen in many COVID-19 patients.</p><graphic position="anchor" xlink:href="43450_2020_104_Figr_HTML" id="MO18"/><p id="Par43">Anti-inflammatory and antineoplastic bisbenzylisoquinoline alkaloids isolated from <italic>Stephania tetrandra</italic> S.Moore, namely cepharanthine (<bold>24</bold>), fangchinoline, and tetrandrine, acted as immunomodulators and inhibited the expression of HCoV-OC43 spike and nucleocapsid proteins (Kim et al. <xref ref-type="bibr" rid="CR51">2019</xref>). After the cells were infected with HCoV-OC43, each compound (5&#x000a0;&#x003bc;M) was added to the wells, and cytokine mRNA was qantified by real-time qRT-PCR. Compound treatment following virus infection reduced the mRNA expression levels of IFN-&#x003b1;1 by almost 20-fold at 4&#x000a0;days post infection, and about 100-fold reduction for IFN-&#x003b2;1 at 3&#x000a0;days post infection (Kim et al. <xref ref-type="bibr" rid="CR51">2019</xref>). According to Islam et al. (<xref ref-type="bibr" rid="CR47">2020</xref>), natural products with anti-coronavirus activity are major constituents of common dietary supplements and can therefore be used to improve the immunity of the general population in pandemics such as COVID-19.</p><graphic position="anchor" xlink:href="43450_2020_104_Figs_HTML" id="MO19"/></sec><sec id="Sec13"><title>Marine Algae and Sponges</title><p id="Par44">According to Kwon et al. (<xref ref-type="bibr" rid="CR59">2013</xref>), five phlorotannins of the edible brown algae <italic>Ecklonia cava</italic> Kjellman competitively inhibit the binding of SARS-CoV spike protein to sialic acids at a concentration of less than 36.6&#x000a0;&#x003bc;M. Two phlorotannins caused the inhibition of SARS-CoV RNA and SARS-CoV protein synthesis in late stages, with IC<sub>50</sub> values of 12.2&#x02009;&#x000b1;&#x02009;2.8 and 14.6&#x02009;&#x000b1;&#x02009;1.3&#x000a0;&#x003bc;M, respectively (Kwon et al. <xref ref-type="bibr" rid="CR59">2013</xref>). The results suggest that compounds isolated from <italic>E. cava</italic> have strong antiviral activity and may be developed into natural therapeutic drugs against SARS-CoV infection (Kwon et al. <xref ref-type="bibr" rid="CR59">2013</xref>). A commercially available <italic>E. cava</italic> extract, Seapolynol&#x02122;, was approved as a new dietary ingredient (NDI) by the US Food and Drug Administration in 2008 (FDA-1995-S-0039-0176) (Lee et al., <xref ref-type="bibr" rid="CR63">2012a</xref>, <xref ref-type="bibr" rid="CR64">b</xref>).</p><p id="Par45">An ethanol extract of the edible brown algae <italic>Ecklonia cava</italic>, Laminariaceae, contained eight phlorotannins that exhibited a dose-dependent (competitive) inhibitory effect on SARS-CoV 3CL<sup>pro</sup> with IC<sub>50</sub> values ranging from 2.7 to 164.7&#x000a0;&#x003bc;M (Park et al. <xref ref-type="bibr" rid="CR90">2013</xref>). Dieckol showed the most potent SARS-CoV 3CL<sup>pro</sup>
<italic>trans</italic>/<italic>cis</italic>-cleavage inhibitory effects. Isolated from the marine alga <italic>Halimeda tuna</italic> (J.Ellis &#x00026; Solander) J.V.Lamouroux, halitunal is a novel diterpene aldehyde with a unique cyclopentadieno[c]pyran ring system. Halitunal displayed antiviral activity against murine coronavirus A59 <italic>in vitro</italic> (Gustafson et al. <xref ref-type="bibr" rid="CR37">2004</xref>). Dercitin, an acridine alkaloid isolated from a marine sponge in the genus <italic>Dercitus</italic> Gray, inhibited the coronavirus A59 strain (EC<sub>50</sub> 1.8&#x000a0;&#x003bc;M).</p><p id="Par46">Mycalamides A and B, protein synthesis inhibitors and antiviral compounds isolated from a sponge <italic>Mycale incrustans</italic> Burton, also inhibited coronavirus A59 (Laport et al. <xref ref-type="bibr" rid="CR60">2009</xref>). <italic>In vivo</italic> activity against coronavirus A59 was observed in mice treated with a 2% mycalamide mixture at a dosage of 0.2&#x000a0;&#x003bc;g/kg daily with 100% survival over a 2-week period (Gallimore <xref ref-type="bibr" rid="CR35">2017</xref>). Triterpenes (thyrsiferol, thyrsiferol acetate, venustatriol) isolated from the red alga <italic>Laurencia venusta</italic> Yamada inhibit coronaviruses, and orthosterol disodium sulfates from the sponge <italic>Petrosia weinbergi</italic> Van Soest inhibit coronavirus A59 (El Sayed <xref ref-type="bibr" rid="CR29">2000</xref>).</p><p id="Par47"><italic>Spirulina platensis</italic> (Gomont) Geitler is a microscopic filamentous alga rich in proteins, vitamins, essential amino acids, minerals, and essential fatty acids like &#x003b3;-linolenic acid. It is produced commercially and sold as a food supplement in health food stores around the world. <italic>Spirulina platensis</italic> (15&#x000a0;g) enhances the immune status and inflammatory and oxidative markers of COVID-19 patients (McCarty and DiNicolantonio <xref ref-type="bibr" rid="CR79">2020</xref>).</p></sec><sec id="Sec14"><title>Regional Traditional Medicine and Antiviral Remedies</title><sec id="Sec15"><title>China</title><p id="Par48">Xiao et al. (<xref ref-type="bibr" rid="CR122">2003</xref>) provided leading insights into the use of fourteen Chinese herbal medicines in the prevention and treatment of SARS. TCM played an important role in the fight against SARS and it was reported by practitioners to be very effective (Lau et al. <xref ref-type="bibr" rid="CR61">2005</xref>). The State Administration of TCM of the People&#x02019;s Republic of China formed a panel of TCM specialists to draw up a technical scheme for the prevention and treatment of SARS-CoV using TCM (Chen et al. <xref ref-type="bibr" rid="CR10">2004</xref>). <italic>Scutellaria baicalensis</italic> is one of the most widely used TCMs and its roots are used to treat inflammation, cancer, and viral and bacterial infections. Baicalin, baicalein, wogonin, and oroxylin A are the main active components in <italic>S. baicalensis.</italic> The most abundant active compound, baicalin, exhibits anti-SARS-CoV properties.</p><p id="Par49">Yeh et al. (<xref ref-type="bibr" rid="CR125">2013</xref>) affirmed that licorice (<italic>Glycyrrhiza uralensis</italic> Fisch. ex DC.) is a common ingredient in prescriptions of TCM. Licorice has antiviral activity against various DNA and RNA viruses including HIV and SARS-CoV. Chinese multi-plant remedy consisting of <italic>Houttuynia cordata</italic> Thunb., <italic>Chrysanthemum morifolium</italic> Ramat., <italic>Artemisia scoparia</italic> Waldst. &#x00026; Kit., <italic>Eupatorium fortunei</italic> Turcz., and <italic>Amomum tsao-ko</italic> Crevost &#x00026; Lemari&#x000e9; was effective in the prevention and treatment of SARS-CoV (Zhang and Chen <xref ref-type="bibr" rid="CR130">2008</xref>). Extracts of <italic>Lonicera japonica</italic> are a common TCM used to treat SARS-CoV (Wang et al. <xref ref-type="bibr" rid="CR115">2014</xref>). To control SARS-CoV in 2003, <italic>L. japonica</italic> was widely used in prescriptions publicly published by the State Administration of TCM.</p><p id="Par50"><italic>Panax ginseng</italic> C.A.Mey., commonly known as ginseng, is a known natural antiviral agent with protective effects against SARS-CoV (Im et al. <xref ref-type="bibr" rid="CR46">2016</xref>). Extracts of <italic>T. sinensis</italic> inhibit SARS-CoV replication (Chen et al. <xref ref-type="bibr" rid="CR8">2008</xref>; Wu et al. <xref ref-type="bibr" rid="CR120">2014</xref>). Extracts of plants <italic>Lycoris radiata</italic> Miq., <italic>Artemisia annua</italic> L., <italic>Pyrrosia lingua</italic> (Thunb.) Farw., and <italic>Lindera aggregata</italic> (Sims) Kosterm. displayed anti-SARS-CoV actions with EC<sub>50</sub> values of 2.4&#x02009;&#x000b1;&#x02009;0.2, 34.5&#x02009;&#x000b1;&#x02009;2.6, 43.2&#x02009;&#x000b1;&#x02009;14.1, and 88.2&#x02009;&#x000b1;&#x02009;7.7&#x000a0;&#x003bc;g/ml, respectively (Li et al. <xref ref-type="bibr" rid="CR68">2005</xref>). An ethanol stem cortex extract of <italic>L. radiata</italic> was very potent against SARS-CoV (EC<sub>50</sub> of 2.1&#x02009;&#x000b1;&#x02009;0.2&#x000a0;nm against the BJ-006 viral strain) (Li et al. <xref ref-type="bibr" rid="CR68">2005</xref>). The active compound lycorine was identified as the anti-SARS-CoV component (EC<sub>50</sub> value of 15.7&#x02009;&#x000b1;&#x02009;1.2&#x000a0;nM). Lycorine shows moderate to potent antiviral activity and reduces viral titers of SARS-CoV (Roy et al. <xref ref-type="bibr" rid="CR98">2018</xref>). Jinchai is a widely used TCM that deters SARS-CoV entry, replication, and lung inflammation induced by viral infection (Zhong et al. <xref ref-type="bibr" rid="CR133">2013</xref>).</p><p id="Par51">Roots and rhizomes of <italic>Glycyrrhiza glabra</italic>, a natural sweetener that contains glycyrrhizin, inhibit virus growth and inactivate virus particles. Glycyrrhizic acid, a major triterpene glycoside isolated from <italic>Glycyrrhiza</italic> species, has activity against several enveloped viruses including SARS-CoV and HIV (Wang et al. <xref ref-type="bibr" rid="CR111">2013</xref>). Diammonium glycyrrhizinate, extracted and purified from <italic>G. uralensis</italic>, inhibited SARS-CoVs (Zhang et al. <xref ref-type="bibr" rid="CR131">2016</xref>). Ho et al. (<xref ref-type="bibr" rid="CR39">2007</xref>) found that two widely used TCM plants in the family Polygonaceae inhibited the interaction of SARS-CoV spike protein and ACE2; the IC<sub>50</sub> values for extracts of the root tubers of <italic>Rheum officinale</italic> Baill. and the root tubers/vines of <italic>Polygonum multiflorum</italic> ranged from 1 to 10&#x000a0;&#x003bc;/ml (Ho et al. <xref ref-type="bibr" rid="CR39">2007</xref>). Chen et al. (<xref ref-type="bibr" rid="CR12">2020</xref>) stated that the mortality of COVID-19 patients in China was markedly reduced because of effective combination therapy of TCM and Western medicines. At least 20 patent TCMs were recommended by government guidelines in the treatment of COVID-19 patients in China (Yang et al. <xref ref-type="bibr" rid="CR124">2020</xref>). Several TCM plant formulae for treating SARS-CoV and COVID-19 were reported by Yang et al. (<xref ref-type="bibr" rid="CR124">2020</xref>).</p></sec><sec id="Sec16"><title>Lebanon</title><p id="Par52">In Lebanon, the oil of <italic>Laurus nobilis</italic> Cav. exerted remarkable activity against SARS-CoV with an IC<sub>50</sub> value of 120&#x000a0;&#x003bc;g/ml and a selectivity index of 4.16 (Loizzo et al. <xref ref-type="bibr" rid="CR76">2008</xref>). An ornamental tree and a member of the Cupressaceae family, <italic>Cupressus sempervirens</italic> L. contains flavonoid derivatives, diterpenes, catechins and flavonolic oligomers, proanthocyanidins, phenolic acids, fatty acids, and essential oils (Orhan and Tumen <xref ref-type="bibr" rid="CR87">2015</xref>). The essential oil of <italic>C. sempervirens</italic> had a mild inhibitory outcome on SARS-CoV activity (700&#x02009;&#x000b1;&#x02009;2.3&#x000a0;&#x003bc;g/ml) (Orhan and Tumen <xref ref-type="bibr" rid="CR87">2015</xref>; Loizzo et al. <xref ref-type="bibr" rid="CR76">2008</xref>). Volatile oils are potential agents for treatment of SARS-CoV (Pasdaran et al. <xref ref-type="bibr" rid="CR91">2016</xref>). An ethanolic extract of <italic>Thymus vulgaris</italic> Sm. found in Lebanon inhibits SARS-CoV (Bekut et al. <xref ref-type="bibr" rid="CR6">2018</xref>). Lebanese essential oils have also been evaluated for their inhibitory activity against SARS-CoV replication <italic>in vitro</italic> by visually scoring the virus-induced cytopathogenic effect post infection.</p></sec><sec id="Sec17"><title>Malaysia</title><p id="Par53">The papain-like protease (PL<sup>pro</sup>) encoded by SARS-CoV cleaves the viral replicase polyprotein. Since this enzymatic activity is important for viral infection, PL<sup>pro</sup> is a target of interest in the development of antiviral therapies. Nine diarylheptanoids from the bark of <italic>Alnus japonica</italic> (Thunb.) Steud. were evaluated for their inhibitory activities against SARS-CoV PL<sup>pro</sup> (Park et al., <xref ref-type="bibr" rid="CR88">2012a</xref>). Hirsutenone was found to be the most potent inhibitor of SARS-CoV PL<sup>pro</sup> (IC<sub>50</sub> of 4.1&#x02009;&#x000b1;&#x02009;0.3&#x000a0;&#x003bc;M).</p><p id="Par54">Seven tanshinones isolated from <italic>Salvia miltiorrhiza</italic> Bunge. were selective inhibitors of SARS-CoV 3CL<sup>Pro</sup> and PL<sup>Pro</sup> viral cysteine proteases with IC<sub>50</sub> values from 0.8 to 30&#x000a0;&#x003bc;M (Park et al. <xref ref-type="bibr" rid="CR89">2012b</xref>). Cryptotanshinone was the most potent inhibitor of SARS-CoV PL<sup>Pro</sup>. Cho et al. (<xref ref-type="bibr" rid="CR20">2013</xref>) obtained 12 flavonoids from the fruits of <italic>Paulownia tomentosa</italic> that function as SARS-CoV PL<sup>Pro</sup> inhibitors. These flavonoids resulted in significant inhibition of SARS-CoV PL<sup>pro</sup> in a dose-dependent manner. Tomentin E exhibited the highest inhibitory effect with an IC<sub>50</sub> of 5&#x02009;&#x000b1;&#x02009;0.06&#x000a0;&#x003bc;M (Cho et al. <xref ref-type="bibr" rid="CR20">2013</xref>). Tomentin isolated from <italic>Sphaeralcea angustifolia</italic> (Cav.) G.Don inhibited PL<sup>Pro</sup> with IC<sub>50</sub> values ranging from 5 to 14.4&#x000a0;&#x003bc;M.</p></sec><sec id="Sec18"><title>Singapore</title><p id="Par55">Chiow et al. (<xref ref-type="bibr" rid="CR19">2016</xref>) conducted <italic>in vitro</italic> virus neutralization assays where an ethyl acetate (EA) fraction of <italic>Houttuynia cordata</italic> and three of its constituent flavonoids were tested on murine coronavirus. With no cytotoxicity, the EA fraction of <italic>H. cordata</italic>, added before the viral adsorption stage, inhibited murine coronavirus (IC<sub>50</sub> 0.98&#x000a0;&#x003bc;g/ml) (Chiow et al. <xref ref-type="bibr" rid="CR19">2016</xref>). The flavonoid quercetin weakly inhibited murine coronavirus with a minimum inhibitory concentration of 125&#x000a0;&#x003bc;g/ml, cytotoxicity CC<sub>50</sub> value of 116.50&#x000a0;&#x003bc;g/ml, and selectivity index of 0.93. The EA fraction and quercetin yielded a long-lasting anti-murine coronavirus effect of up to 6&#x000a0;days. Overall, this study demonstrated that the EA fraction of <italic>H. cordata</italic> and its flavonoid component, quercetin, neutralizes murine coronavirus <italic>in vitro</italic> (Chiow et al. <xref ref-type="bibr" rid="CR19">2016</xref>).</p></sec><sec id="Sec19"><title>South Africa</title><p id="Par56">The EPs&#x000ae; 7630 liquid herbal drug Umckaloabo&#x000ae;, a 100&#x000a0;&#x003bc;g/ml extract of <italic>Pelargonium sidoides</italic> DC., exerts anti-influenza virus activity <italic>in vitro</italic> and <italic>in vivo</italic> (Theisen and Muller <xref ref-type="bibr" rid="CR108">2012</xref>). Discovered in South Africa, Umckaloabo, a decoction of the roots of <italic>Pelargonium sidoides</italic>, was originally used by Zulu traditional healers as a remedy for acute bronchitis. Umckaloabo&#x000ae; is known to inhibit the entry and replication of HCoV-229E (Michaelis et al. <xref ref-type="bibr" rid="CR81">2011</xref>). It is a common medication for acute bronchitis in South Africa and Germany.</p></sec></sec><sec id="Sec20"><title>Clinical Trials</title><p id="Par57">Although uncontrolled human trials for SARS-CoV anti-infectives have been reported, no randomized controlled trials with a specific anti-coronavirus agent had been conducted with respect to therapy or prophylaxis (Wong and Yuen <xref ref-type="bibr" rid="CR118">2008</xref>). There had not been any clinical trials for drugs of infections caused by HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1 (Wong and Yuen, <xref ref-type="bibr" rid="CR118">2008</xref>).</p><p id="Par58">Chen et al. (<xref ref-type="bibr" rid="CR10">2004</xref>) urged that randomized placebo control trials should assess the efficacy of intravenous baicalin (<bold>10</bold>) for the treatment of SARS especially in developing countries where such formulations were available and affordable. In a randomized double-blinded placebo controlled trial, quercetin supplementation in doses of 500 and 1000&#x000a0;mg/day for 12&#x000a0;weeks significantly increased plasma quercetin levels with no reported side effects, but neither decreased total number of upper respiratory tract infection sick days nor reduced symptomatology in all subjects (Heinz et al. <xref ref-type="bibr" rid="CR38">2010</xref>). Liu et al. (<xref ref-type="bibr" rid="CR74">2012</xref>) reviewed 12 randomized controlled trials and one quasi-randomized controlled trial where 12 herbal remedies were administered on 640 SARS patients.</p><p id="Par59">Case reports, case series, controlled observational studies, and randomized clinical trials provided compelling data that TCM had beneficial effects in the treatment or prevention of SARS (Lau et al. <xref ref-type="bibr" rid="CR61">2005</xref>). For example, the rate of fatality in Hong Kong and Singapore was approximately 18%, while the rate for Beijing was initially more than 52% until the 5th May 2003 when it decreased to 4%, and then to 1% after 20th May 2003 (Yang et al. <xref ref-type="bibr" rid="CR124">2020</xref>). The dramatic reduction in fatality in Beijing was associated with the use of TCM as a supplement to conventional therapy (Chen and Nakamura <xref ref-type="bibr" rid="CR13">2004</xref>). Lau et al. (<xref ref-type="bibr" rid="CR61">2005</xref>) reported that during the SARS outbreak of 2002/2003, 1063 volunteers including 926 hospital workers and 37 laboratory technicians working in high-risk virus laboratories used TCM, namely Sang Ju Yin plus Yu Ping Feng San. Compared with the 0.4% of infection in the placebo group, none of the TCM users was infected. In a controlled clinical study, Hsu et al. (<xref ref-type="bibr" rid="CR42">2006b</xref>) reported that supplementary treatment with TCM resulted in marked relief of symptoms and truncated the disease course. The clinical benefits of TCM were supported by laboratory studies especially for the use of glycyrrhizin (<bold>5</bold>), baicalin (<bold>10</bold>), and MOL376, an inhibitor of cathepsin L that could become a lead compound for SARS therapy (Yang et al. <xref ref-type="bibr" rid="CR124">2020</xref>).</p><p id="Par60">After a review of eight randomized controlled trials, Liu et al. (<xref ref-type="bibr" rid="CR73">2004</xref>) resolved that a combination of TCM with conventional medicine had beneficial effects such as decrease of mortality, relief of symptoms, and control of fungal infections in patients with SARS. However, the trial evidence was not sufficient enough due to the lack of methodological rigour. In a review of 90 peer-reviewed Chinese publications after the SARS epidemic of 2002/2003, Leung (<xref ref-type="bibr" rid="CR65">2007</xref>) concluded that TCM used together with conventional treatment had positive effects including better control of fever and quicker amelioration of chest infection. Wu et al. (<xref ref-type="bibr" rid="CR121">2008</xref>) urged a re-run of clinical trials involving TCM for the treatment of SARS because the validity of results was jeopardized by questionable trial designs and experimental biases. TCM should be evaluated in carefully designed clinical trials, either used alone or integrated with Western medicine, to cover the prevention and treatment of patients suffering from COVID-19 pneumonia (Ling <xref ref-type="bibr" rid="CR72">2020</xref>). By mid-March 2020, at least 14 TCM clinical trials with a total of 2714 patients were ongoing for the treatment of SARS-CoV-2 infection (Yang et al. <xref ref-type="bibr" rid="CR124">2020</xref>). Chinese treatment data showed that patented TCM had good therapeutic efficacy in the treatment of COVID-19, with minimal adverse reactions (Zhuang et al. <xref ref-type="bibr" rid="CR139">2020</xref>).</p></sec><sec id="Sec21"><title>Perspective on Future Directions</title><p id="Par61">Empirical data on SARS-CoV treatments are scarce (Wong and Yuen <xref ref-type="bibr" rid="CR118">2008</xref>), and the majority of viral diseases do not have targeted drugs or vaccines (Mahapatra et al. <xref ref-type="bibr" rid="CR78">2019</xref>). Although the ongoing SARS-CoV-2 global pandemic should remind scientists that current options for treating life-threatening zoonotic coronavirus infections are very limited (Wu et al. <xref ref-type="bibr" rid="CR119">2020</xref>), medicinal plants offer a strong pipeline for the discovery of novel lead compounds that can be converted into new drugs to treat COVID-19. Medicinal plants hold great promise for drug development against SARS-CoV-2, but there is paucity of research on the development of anti-SARS-CoV-2 drugs from natural products. In addition, most of the data on natural products with activity against HCoVs are from non-clinical and pre-clinical studies (Islam et al. <xref ref-type="bibr" rid="CR47">2020</xref>).</p><p id="Par62">Potential anti-coronavirus therapies can be divided into two categories depending on their target: those that act on the human immune system or human cells, and those that interfere with the coronavirus itself (Wu et al. <xref ref-type="bibr" rid="CR119">2020</xref>). The unmet need for pharmacologically potent and safe antivirals ought to be fulfilled by thinking out of the box and indigenous knowledge of medicinal plants may be a masterstroke against deadly infectious diseases such as COVID-19 (Mahapatra et al. <xref ref-type="bibr" rid="CR78">2019</xref>). Vellingiri et al. (<xref ref-type="bibr" rid="CR109">2020</xref>) postulated that medicinal plants are potential sources of drugs for the treatment of COVID-19. Ling (<xref ref-type="bibr" rid="CR72">2020</xref>) also submitted that traditional plant medicines are a good source of natural compounds for the discovery and development of drugs against SARS-CoV-2. So, the mortality of COVID-19 patients in China was limited by the use of TCM. As the growing COVID-19 global pandemic reformats the classical norms of pharmaceutical and clinical interventions, this review is a poignant reminder that repurposing of current medicinal plants and other natural products to treat COVID-19 should become part of our new vernacular health system.</p><p id="Par63">Comparative genomics lends credence to the repurposing of current anti-SARS natural products for the treatment of COVID-19. This is because the genome sequence of SARS-CoV is very similar to that of SARS-CoV-2 (Tahir ul Qamar et al. <xref ref-type="bibr" rid="CR107">2020</xref>). Phylogenetic analysis of whole genomes reveals that SARS-CoV-2 shares 79.7% nucleotide sequence identity with SARS-CoV (Wang et al. <xref ref-type="bibr" rid="CR113">2020a</xref>; Zhou et al., <xref ref-type="bibr" rid="CR135">2020a</xref>, <xref ref-type="bibr" rid="CR137">b</xref>). Compared with SARS-CoV, the envelope and nucleocapsid proteins of SARS-CoV-2 share sequence identities of 96% and 89.6%, respectively (Zhou et al., <xref ref-type="bibr" rid="CR135">2020a</xref>, <xref ref-type="bibr" rid="CR137">b</xref>). The virion of SARS-CoV-2 consists of a similar structure as SARS-CoV and MERS-CoV. Like SARS-CoV, SARS-CoV-2 also uses ACE2 as its cellular receptor to enter host cells (Zhou et al., <xref ref-type="bibr" rid="CR135">2020a</xref>, <xref ref-type="bibr" rid="CR137">b</xref>). The chymotrypsin-like protease (3CL<sup>pro</sup>) of SARS-CoV is conserved and shares 99.02% sequence identity with SARS-CoV-2 3CL<sup>pro</sup> (Tahir ul Qamar et al. <xref ref-type="bibr" rid="CR107">2020</xref>). These comparative genomic similarities signify one epic biomedical prospect: if medicinal plants used against SARS-CoV and MERS-CoV are carefully repurposed, they could be effective against SARS-CoV-2. In this new normality, natural products should become part of the COVID-19 survival kit.</p><p id="Par64">In the absence of an effective and safe drug that inhibits SARS-CoV-2, the use of antimalarial plants and synthetic drugs has gained traction in the treatment of COVID-19. The notion that antimalarial plants in the genus <italic>Artemisia</italic> L. can be repurposed to prevent and treat COVID-19 has often been associated with experimental data that chloroquine inhibits the replication of viruses. Chloroquine inhibits chikungunya virus replication in Vero A cells (IC<sub>50</sub> 7&#x000a0;&#x003bc;M, IC<sub>90</sub> 15&#x000a0;&#x003bc;M, selectivity index&#x02009;=&#x02009;37.14) in a dose-dependent manner. Chloroquine, whose chemical structure mimics nucleoside analogues, has <italic>in vitro</italic> activity against SARS-CoV and SARS-CoV-2 (Wang et al. <xref ref-type="bibr" rid="CR113">2020a</xref>). An antimalarial drug known since 1934, chloroquine blocks HIV-1 and HCoVs at a very early stage; it also inhibits the replication of MERS-CoV in a dose-dependent mode (EC<sub>50</sub> of 3&#x000a0;&#x003bc;M) (de Wilde et al. <xref ref-type="bibr" rid="CR26">2014</xref>). Chloroquine exerts antiviral as well as immunomodulatory properties. Chloroquine (EC<sub>50</sub> of 1.13&#x000a0;&#x003bc;M against SARS-CoV-2) blocks viral infection by increasing the endosomal pH required for viral fusion (Vellingiri et al. <xref ref-type="bibr" rid="CR109">2020</xref>). A 9-aminoquinoline, chloroquine inhibits SARS-CoV replication and downregulates IFN-&#x003b3; and TNF-&#x003b1; production in mice (Prinsloo et al. <xref ref-type="bibr" rid="CR94">2018</xref>). In the first half of 2020, clinical trials (NCT04261517 and NCT04307693) of hydroxychloroquine treatment for COVID-19 were underway in China (Wang et al. <xref ref-type="bibr" rid="CR114">2020b</xref>). The World Health Organization announced it would resume its halted randomized controlled trials to find out whether hydroxychloroquine was able to prevent COVID-19. This was after the <italic>Lancet</italic> on 4 June 2020, due to concerns with respect to the veracity of the data and analyses, retracted an influential article which had earlier reported that hydroxychloroquine increased the mortality of COVID-19 patients. On 15 June 2020, the US Food and Drug Administration revoked the emergence use of hydroxychloroquine to treat COVID-19 patients after reports that the drug increases the risk of cardiovascular side effects including cardiomyopathy and cardiac arrest.</p><p id="Par65">Taken together, these developments signify that many countries should carefully evaluate the efficacy and safety of natural antimalarial agents for the possible treatment of COVID-19. Rich in flavonoids such as acacetin, genkwanin, and 7-methoxyacacetin, leaf extracts of <italic>Artemisia afra</italic> Jacq., a common antimalarial remedy in Kenya, Rwanda, and Zambia (Chinsembu <xref ref-type="bibr" rid="CR15">2015</xref>), should be carefully evaluated in COVID-19 patients. The need for medicinal plants and other natural products to treat COVID-19 patients is urgent especially in Africa where health systems grapple with high caseloads of HIV/AIDS and malaria in addition to being heavily under-resourced in terms of funding and staff. Overall, plants with antiplasmodial (Chinsembu <xref ref-type="bibr" rid="CR15">2015</xref>), anti-tuberculosis (Chinsembu <xref ref-type="bibr" rid="CR17">2016b</xref>), and anti-HIV replication (Chinsembu <xref ref-type="bibr" rid="CR18">2019</xref>) activities may present good prospects for the discovery of new active compounds with anti-SARS-CoV-2 action. <italic>Pechuel-loeschea leubnitziae</italic> O. Hoffm. (Asteraceae), an indigenous plant used to &#x0201c;steam&#x0201d; patients suffering from pneumonia and coughs in Namibia (Kadhila et al. <xref ref-type="bibr" rid="CR48">2020</xref>; Mofolo et al. <xref ref-type="bibr" rid="CR83">2020</xref>), should also be evaluated for anti-COVID-19 function. High-throughput screening of these plants should be conducted, and computational techniques can quicken the process.</p><p id="Par66">Moreover, plant active compounds should be subjected to absorption, distribution, metabolism, and excretion (ADME) evaluation to verify that oral administration would be effective (Zhang et al. <xref ref-type="bibr" rid="CR127">2020</xref>). Analysis of structure-activity relationships may be helpful in understanding the mechanisms of certain active compounds such as myricetin (<bold>5</bold>), baicalein (<bold>6</bold>), and quercetin. Further studies including <italic>in silico</italic> molecular docking simulations should be done to investigate the binding affinities of plant active compounds to SARS-CoV-2. A docking analysis can test whether the active compound has the potential to directly interact with SARS-CoV-2 proteins (Zhang et al. <xref ref-type="bibr" rid="CR127">2020</xref>). Application of structure-based drug design strategies may aid in the development of novel SARS-CoV-2 inhibitors from natural compounds. To predict the general <italic>in vivo</italic> effects of the natural compounds, network pharmacology analysis can be carried out.</p><p id="Par67">Only 0.0004% plant samples may directly lead to a commercial drug (Chinsembu <xref ref-type="bibr" rid="CR16">2016a</xref>). Thus, there are few plant-derived anti-SARS agents in clinical trials. From 2012 to 2017, only twelve new antivirals were approved by the US Food and Drug Administration; eight were for the treatment of pathologies related to hepatitis C virus and two were combinations of anti-HIV drugs (Mercorelli et al. <xref ref-type="bibr" rid="CR80">2018</xref>). Since less than 15% of plant diversity has been explored for pharmaceutical purposes (Chinsembu, <xref ref-type="bibr" rid="CR16">2016a</xref>), the transition from natural product to anti-SARS-CoV-2 drug prototypes is a daunting reality as much as it is a beautiful prospect.</p><p id="Par68">This review shows that plants, fungi, and marine organisms have anti-SARS-CoV properties. Many of these plants, fungi, and marine organisms have other pharmacological benefits because structural diversity and adaptation to various environmental conditions induce them to synthesize defensive compounds with assorted biological activities (Prinsloo et al. <xref ref-type="bibr" rid="CR94">2018</xref>). Corollary, diverse plant secondary metabolites are an important library of novel lead compounds that may be functional against SARS-CoV-2. Bio-assay-guided fractionation of medicinal plant extracts may provide a quicker pipeline for the discovery of novel compounds against SARS-CoV-2.</p><p id="Par69">An examination of the research publications on anti-SARS natural products cited in this review shows that about 8 out of 10 are authored by the Chinese. Since the Chinese represent about 80% of all research efforts and publications on anti-SARS natural products, there is 80% chance that the next big discovery of novel natural products to treat COVID-19 will be from TCM. China is the world leader in research and development for innovative anti-SARS agents from natural products. By all intents and purposes, the first well-researched and clinically proven herbal remedy for COVID-19 will most likely be discovered and developed in China.</p><p id="Par70">The most notable gap identified in the current literature is that many countries in Africa, Asia (except China), Australia/Oceania, Europe, North America, and South America lag behind in terms of research efforts on anti-coronavirus remedies from medicinal plants and other natural products. In many countries all over the world, there is need to conduct detailed ethnobotanical studies to establish putative anti-SARS-CoV-2 medicinal plants and their active compounds. The search for new anti-SARS-CoV-2 agents should be rigorously extended to marine organisms. This review shows that there is a dearth of experimental data on posology and cytotoxicity of plant extracts and active compounds with <italic>in vitro</italic> activity against SARS-CoV-2. More studies on pan-assay interference compounds (PAINS) and SARS-CoV-2 immunomodulatory agents from plants and other natural products should be conducted. There is also lack of pharmacological and rigorous human clinical trial data in relation to natural products for treating COVID-19.</p></sec><sec id="Sec22"><title>Conclusions</title><p id="Par71">The world is in the middle of a COVID-19 pandemic. Although the deadly threat posed by the current COVID-19 pandemic requires the development of new therapeutic agents, there are currently no efficacious and safe vaccines or drugs to prevent or treat this highly infectious disease. Even in developed nations, blockbuster vaccines or drugs have not yet been developed or approved for the prevention and treatment of COVID-19. Only one synthetic drug (remdesivir) has been approved for emergency use in the USA. Compared with placebo, remdesivir did not significantly reduce the mortality of COVID-19 patients in clinical trials. Against this backdrop, this review provides a modest but insightful snapshot of medicinal plants, fungi, and marine organisms that contain putative active compounds that inhibit SARS-CoV-2.</p><p id="Par72">Data in this review show two recurring motifs. The first one is that the search for herbal remedies against COVID-19 is more intense in China than in any other part of the world. The second is that most putative anti-SARS-CoV-2 remedies contain active compounds that inhibit HCoVs at the cellular and molecular levels. Since structure dictates function, many of these compounds inhibit SARS-CoV replication because their chemical structures mimic nucleoside analogues. While many of the natural products possess anti-SARS-CoV properties, their extracts and active compounds should be evaluated for human cytotoxicity and dosage. Putative anti-SARS-CoV-2 extracts and active compounds should be rigorously tested in animal and randomized placebo clinical trials.</p><p id="Par73">Due to the current lack of effective and safe drugs, natural products presented in this review may form part of the health beliefs, self-medication choices, and self-efficacy practices that people may use to manage COVID-19. Natural products presented in this paper form a repertoire of promising leads that may be repurposed into novel drugs, nutraceuticals, and supplements for COVID-19. If there is a long-term remedy for COVID-19, it must lie in Mother Nature&#x02019;s pharmacy of SARS-CoV-2 inhibitors and immunomodulators from plants, fungi, and marine organisms.</p></sec></body><back><ack><p>The author is grateful to the anonymous reviewers and to Professor Rogelio Pereda-Miranda, Editor-in-Chief of <italic>Revista Brasileira de Farmacognosia</italic>, for their help in improving the original manuscript.</p><sec id="FPar1"><title>Code Availability</title><p id="Par74">Not applicable</p></sec></ack><notes notes-type="author-contribution"><title>Author&#x02019;s Contributions</title><p>Kazhila C. Chinsembu (Full Professor, University of Namibia) designed the review, did the literature search, and wrote the paper.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>All data submitted incl. supplementary material.</p></notes><notes><title>Compliance with Ethical Standards</title><notes id="FPar2"><title>Protection of Human and Animal Subjects</title><p id="Par75">The author declares that no experiments were performed on humans or animals for this study.</p></notes><notes id="FPar3"><title>Confidentiality of Data</title><p id="Par76">The author declares that no patient data appear in this article.</p></notes><notes id="FPar4"><title>Right to Privacy and Informed Consent</title><p id="Par77">The author declares that no patient data appear in this article.</p></notes><notes id="FPar5" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par78">The author declares that there is no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>PI</given-names></name><name><surname>Ianevski</surname><given-names>A</given-names></name><name><surname>Lysvand</surname><given-names>H</given-names></name><name><surname>Vitkauskiene</surname><given-names>A</given-names></name><name><surname>Oksenych</surname><given-names>V</given-names></name><name><surname>Bj&#x000f8;r&#x000e5;s</surname><given-names>M</given-names></name><name><surname>Telling</surname><given-names>K</given-names></name><name><surname>Lutsar</surname><given-names>I</given-names></name><name><surname>Dampis</surname><given-names>U</given-names></name><name><surname>Irie</surname><given-names>Y</given-names></name><name><surname>Tenson</surname><given-names>T</given-names></name></person-group><article-title>Discovery and development of safe-in-man broad-spectrum antiviral agents</article-title><source>Int J Infect Dis</source><year>2020</year><volume>93</volume><fpage>268</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.02.018</pub-id><?supplied-pmid 7128205?><pub-id pub-id-type="pmid">32081774</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>PI</given-names></name><name><surname>Krpina</surname><given-names>K</given-names></name><name><surname>Ianevski</surname><given-names>A</given-names></name><name><surname>Shtaida</surname><given-names>N</given-names></name><name><surname>Jo</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Koit</surname><given-names>S</given-names></name><name><surname>Tenson</surname><given-names>T</given-names></name><name><surname>Hukkanen</surname><given-names>V</given-names></name><name><surname>Anthonsen</surname><given-names>MW</given-names></name><name><surname>Bjoras</surname><given-names>M</given-names></name></person-group><article-title>Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>964</fpage><pub-id pub-id-type="doi">10.3390/v11100964</pub-id><?supplied-pmid 6832696?><pub-id pub-id-type="pmid">6832696</pub-id></element-citation></ref><ref id="CR3"><mixed-citation publication-type="other">Asif M, Saleem M, Saadullah M, Yaseen HS, Al Zarzour R (2020) COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. Inflammopharmacology. 10.1007/s10787-020-00744-0</mixed-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltina</surname><given-names>LA</given-names></name><name><surname>Zarubaev</surname><given-names>VV</given-names></name><name><surname>Baltina</surname><given-names>LA</given-names></name><name><surname>Orshanskaya</surname><given-names>IA</given-names></name><name><surname>Fairushina</surname><given-names>AI</given-names></name><name><surname>Kiselev</surname><given-names>OI</given-names></name><name><surname>Yunusov</surname><given-names>MS</given-names></name></person-group><article-title>Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors</article-title><source>Bioorg Med Chem Lett</source><year>2015</year><volume>25</volume><fpage>1742</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.02.074</pub-id><?supplied-pmid 7127794?><pub-id pub-id-type="pmid">25801933</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>S</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>SS</given-names></name><name><surname>Lohan</surname><given-names>S</given-names></name><name><surname>Bhardwaj</surname><given-names>V</given-names></name><name><surname>Syan</surname><given-names>N</given-names></name><name><surname>Jyoti</surname><given-names>S</given-names></name></person-group><article-title>Tea: a native source of antimicrobial agents</article-title><source>Food Res Int</source><year>2013</year><volume>53</volume><fpage>568</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.foodres.2013.01.032</pub-id><?supplied-pmid 7126541?><pub-id pub-id-type="pmid">7126541</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekut</surname><given-names>M</given-names></name><name><surname>Brki&#x00107;</surname><given-names>S</given-names></name><name><surname>Kladar</surname><given-names>N</given-names></name><name><surname>Dragovi&#x00107;</surname><given-names>G</given-names></name><name><surname>Gavari&#x00107;</surname><given-names>N</given-names></name><name><surname>Bo&#x0017e;in</surname><given-names>B</given-names></name></person-group><article-title>Potential of selected Lamiaceae plants in anti (retro) viral therapy</article-title><source>Pharmacol Res</source><year>2018</year><volume>133</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2017.12.016</pub-id><pub-id pub-id-type="pmid">29258916</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>FR</given-names></name><name><surname>Yen</surname><given-names>CT</given-names></name><name><surname>Ei-Shazly</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>WH</given-names></name><name><surname>Yen</surname><given-names>MH</given-names></name><name><surname>Lin</surname><given-names>KH</given-names></name><name><surname>Wu</surname><given-names>YC</given-names></name></person-group><article-title>Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of <italic>Euphorbia neriifolia</italic></article-title><source>Nat Prod Commun</source><year>2012</year><volume>7</volume><fpage>1934578X1200701</fpage><pub-id pub-id-type="doi">10.1177/1934578X1200701103</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Michaelis</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>HK</given-names></name><name><surname>Tsai</surname><given-names>CC</given-names></name><name><surname>Yang</surname><given-names>KD</given-names></name><name><surname>Wu</surname><given-names>YC</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title><italic>Toona sinensi</italic>s Roem tender leaf extract inhibits SARS coronavirus replication</article-title><source>J Ethnopharmacol</source><year>2008</year><volume>120</volume><fpage>108</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2008.07.048</pub-id><?supplied-pmid 7127248?><pub-id pub-id-type="pmid">18762235</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CN</given-names></name><name><surname>Lin</surname><given-names>CPC</given-names></name><name><surname>Huang</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Hsieh</surname><given-names>HP</given-names></name><name><surname>Liang</surname><given-names>PH</given-names></name><name><surname>Hsu</surname><given-names>JTA</given-names></name></person-group><article-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3&#x02032;-digallate (TF3)</article-title><source>Evid Based Complement Alternat Med</source><year>2005</year><volume>2</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh081</pub-id><?supplied-pmid 1142193?><pub-id pub-id-type="pmid">15937562</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Kao</surname><given-names>RY</given-names></name><name><surname>Lu</surname><given-names>HT</given-names></name><name><surname>Fan</surname><given-names>KW</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Tsui</surname><given-names>WH</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Lee</surname><given-names>TS</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name></person-group><article-title><italic>In vitro</italic> susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</article-title><source>J Clin Virol</source><year>2004</year><volume>31</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2004.03.003</pub-id><?supplied-pmid 7128415?><pub-id pub-id-type="pmid">15288617</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Liew</surname><given-names>OW</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Puah</surname><given-names>CM</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name></person-group><article-title>Binding interaction of quercetin-3-&#x003b2;-galactoside and its synthetic derivatives with SARS-CoV 3CL<sup>pro</sup>: structure&#x02013;activity relationship studies reveal salient pharmacophore features</article-title><source>Bioorg Med Chem</source><year>2006</year><volume>14</volume><fpage>8295</fpage><lpage>8306</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2006.09.014</pub-id><?supplied-pmid 7125754?><pub-id pub-id-type="pmid">17046271</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Quan</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><article-title>A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>683</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1002/jmv.25755</pub-id><pub-id pub-id-type="pmid">32162699</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS</article-title><source>Phytother Res</source><year>2004</year><volume>18</volume><fpage>592</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1002/ptr.1485</pub-id><pub-id pub-id-type="pmid">15305324</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>PW</given-names></name><name><surname>Ng</surname><given-names>LT</given-names></name><name><surname>Chiang</surname><given-names>LC</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name></person-group><article-title>Antiviral effects of saikosaponins on human coronavirus 229E <italic>in vitro</italic></article-title><source>Clin Exp Pharmacol Physiol</source><year>2006</year><volume>33</volume><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2006.04415.x</pub-id><?supplied-pmid 7162031?><pub-id pub-id-type="pmid">16789928</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinsembu</surname><given-names>KC</given-names></name></person-group><article-title>Plants as antimalarial agents in Sub-Saharan Africa</article-title><source>Acta Trop</source><year>2015</year><volume>152</volume><fpage>32</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2015.08.009</pub-id><pub-id pub-id-type="pmid">26297798</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chinsembu</surname><given-names>KC</given-names></name></person-group><source>Green Medicines: pharmacy of natural products for HIV and five AIDS-related infections</source><year>2016</year><publisher-loc>Toronto</publisher-loc><publisher-name>Africa in Canada Press</publisher-name></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinsembu</surname><given-names>KC</given-names></name></person-group><article-title>Tuberculosis and nature&#x02019;s pharmacy of putative anti-tuberculosis agents</article-title><source>Acta Trop</source><year>2016</year><volume>153</volume><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2015.10.004</pub-id><pub-id pub-id-type="pmid">26464047</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinsembu</surname><given-names>KC</given-names></name></person-group><article-title>Chemical diversity and activity profiles of HIV-1 reverse transcriptase inhibitors from plants</article-title><source>Rev Bras</source><year>2019</year><volume>29</volume><fpage>504</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.bjp.2018.10.006</pub-id></element-citation></ref><ref id="CR19"><mixed-citation publication-type="other">Chiow KH, Phoon MC, Putti T, Tan BK, Chow VT (2016) Evaluation of antiviral activities of <italic>Houttuynia cordata</italic> Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. Asian Pac J Trop Med 9. 10.1016/j.apjtm.2015.12.002</mixed-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>JK</given-names></name><name><surname>Curtis-Long</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Ryu</surname><given-names>HW</given-names></name><name><surname>Yuk</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name></person-group><article-title>Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of <italic>Paulownia tomentosa</italic></article-title><source>Bioorg Med Chem</source><year>2013</year><volume>21</volume><fpage>3051</fpage><lpage>3057</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.03.027</pub-id><?supplied-pmid 7126831?><pub-id pub-id-type="pmid">23623680</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Ahn</surname><given-names>YJ</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>DH</given-names></name></person-group><article-title>Antiviral activity of quercetin 7-rhamnoside against porcine epidemic diarrhea virus</article-title><source>Antivir Res</source><year>2009</year><volume>81</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2008.10.002</pub-id><pub-id pub-id-type="pmid">18992773</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>KT</given-names></name><name><surname>Wong</surname><given-names>AY</given-names></name><name><surname>Kaewpreedee</surname><given-names>P</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Hui</surname><given-names>KP</given-names></name><name><surname>Chu</surname><given-names>DK</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name><name><surname>Cheung</surname><given-names>PP</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name></person-group><article-title>Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication <italic>in vitro</italic></article-title><source>Antivir Res</source><year>2020</year><volume>178</volume><fpage>104786</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104786</pub-id><pub-id pub-id-type="pmid">32251767</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Morgenstern</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>P</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>2045</fpage><lpage>2046</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(03)13615-x</pub-id><?supplied-pmid 7112442?><pub-id pub-id-type="pmid">12814717</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuong</surname><given-names>NX</given-names></name><name><surname>Minh</surname><given-names>CV</given-names></name><name><surname>Kiem</surname><given-names>PV</given-names></name><name><surname>Huong</surname><given-names>HT</given-names></name><name><surname>Ban</surname><given-names>NK</given-names></name><name><surname>Nhiem</surname><given-names>NX</given-names></name><name><surname>Tung</surname><given-names>NH</given-names></name><name><surname>Jung</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name></person-group><article-title>Inhibitors of osteoclast formation from rhizomes of <italic>Cibotium barometz</italic></article-title><source>J Nat Prod</source><year>2009</year><volume>72</volume><fpage>1673</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.1021/np9004097</pub-id><pub-id pub-id-type="pmid">19739599</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Recent highlights in the development of new antiviral drugs</article-title><source>Curr Opin Microbiol</source><year>2005</year><volume>8</volume><fpage>552</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2005.08.010</pub-id><?supplied-pmid 7108330?><pub-id pub-id-type="pmid">16125443</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Jochmans</surname><given-names>D</given-names></name><name><surname>Posthuma</surname><given-names>CC</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>JC</given-names></name><name><surname>Van Nieuwkoop</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name><name><surname>Van Den Hoogen</surname><given-names>BG</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Snijder</surname><given-names>EJ</given-names></name></person-group><article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>4875</fpage><lpage>4884</lpage><pub-id pub-id-type="doi">10.1128/AAC.03011-14</pub-id><?supplied-pmid 4136071?><pub-id pub-id-type="pmid">24841269</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>ZH</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Hu</surname><given-names>YX</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name></person-group><article-title>The natural compound homoharringtonine presents broad antiviral activity <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Viruses</source><year>2018</year><volume>10</volume><fpage>601</fpage><pub-id pub-id-type="doi">10.3390/v10110601</pub-id><?supplied-pmid 6266276?><pub-id pub-id-type="pmid">6266276</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Huyiligeqi</surname><given-names>NJ</given-names></name></person-group><article-title>Emodin: a review of its pharmacology, toxicity and pharmacokinetics</article-title><source>Phytother Res</source><year>2016</year><volume>30</volume><fpage>1207</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1002/ptr.5631</pub-id><?supplied-pmid 7168079?><pub-id pub-id-type="pmid">27188216</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Sayed</surname><given-names>KA</given-names></name></person-group><article-title>Natural products as antiviral agents</article-title><source>Stud Nat Prod Chem</source><year>2000</year><volume>24</volume><fpage>473</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/S1572-5995(00)80051-4</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>AA</given-names></name></person-group><article-title>Anti-HCV, nucleotide inhibitors, repurposing against COVID-19</article-title><source>Life Sci</source><year>2020</year><volume>248</volume><fpage>117477</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117477</pub-id><?supplied-pmid 32119961?><pub-id pub-id-type="pmid">32119961</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engler</surname><given-names>O</given-names></name><name><surname>Strasser</surname><given-names>M</given-names></name><name><surname>Signer</surname><given-names>J</given-names></name><name><surname>Schoop</surname><given-names>R</given-names></name></person-group><article-title>Neutralizing activity of <italic>Echinacea purpurea</italic> on coronaviruses including highly pathogenic Middle-East-Respiratory Syndrome Virus (MERS-CoV)</article-title><source>Planta Med Int Open</source><year>2017</year><volume>4</volume><fpage>S1</fpage><lpage>S202</lpage><pub-id pub-id-type="doi">10.1055/s-0037-1608557</pub-id></element-citation></ref><ref id="CR32"><mixed-citation publication-type="other">Enmozhi SK, Raja K, Sebastine I, Joseph J (2020) Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an <italic>in silico</italic> approach. J Biomol Struct Dyn:1&#x02013;7. 10.1080/07391102.2020.1760136</mixed-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>N</given-names></name><name><surname>Vitoria</surname><given-names>M</given-names></name><name><surname>Rangaraj</surname><given-names>A</given-names></name><name><surname>Norris</surname><given-names>SL</given-names></name><name><surname>Calmy</surname><given-names>A</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name></person-group><article-title>Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment</article-title><source>J Int AIDS Soc</source><year>2020</year><volume>23</volume><fpage>e25489</fpage><pub-id pub-id-type="doi">10.1002/jia2.25489</pub-id><?supplied-pmid 7158851?><pub-id pub-id-type="pmid">32293807</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forni</surname><given-names>D</given-names></name><name><surname>Cagliani</surname><given-names>R</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Sironi</surname><given-names>M</given-names></name></person-group><article-title>Molecular evolution of human coronavirus genomes</article-title><source>Trends Microbiol</source><year>2017</year><volume>25</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.09.001</pub-id><pub-id pub-id-type="pmid">27743750</pub-id></element-citation></ref><ref id="CR35"><mixed-citation publication-type="other">Gallimore W (2017) Marine metabolites: oceans of opportunity. Pharmacognosy, Academic Press, pp. 377&#x02013;400. 10.1016/B978-0-12-802104-0.00018-4</mixed-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>WB</given-names></name><name><surname>Lahore</surname><given-names>H</given-names></name><name><surname>McDonnell</surname><given-names>SL</given-names></name><name><surname>Baggerly</surname><given-names>CA</given-names></name><name><surname>French</surname><given-names>CB</given-names></name><name><surname>Aliano</surname><given-names>JL</given-names></name><name><surname>Bhattoa</surname><given-names>HP</given-names></name></person-group><article-title>Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><fpage>988</fpage><pub-id pub-id-type="doi">10.3390/nu12040988</pub-id><?supplied-pmid 7231123?><pub-id pub-id-type="pmid">7231123</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafson</surname><given-names>KR</given-names></name><name><surname>Oku</surname><given-names>N</given-names></name><name><surname>Milanowski</surname><given-names>DJ</given-names></name></person-group><article-title>Antiviral marine natural products</article-title><source>Curr Med Chem: Anti-Infect Agents</source><year>2004</year><volume>3</volume><fpage>233</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.2174/15680120433539</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname><given-names>SA</given-names></name><name><surname>Henson</surname><given-names>DA</given-names></name><name><surname>Austin</surname><given-names>MD</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Nieman</surname><given-names>DC</given-names></name></person-group><article-title>Quercetin supplementation and upper respiratory tract infection: a randomized community clinical trial</article-title><source>Pharmacol Res</source><year>2010</year><volume>62</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2010.05.001</pub-id><?supplied-pmid 7128946?><pub-id pub-id-type="pmid">20478383</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TY</given-names></name><name><surname>Wu</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Hsiang</surname><given-names>CY</given-names></name></person-group><article-title>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction</article-title><source>Antivir Res</source><year>2007</year><volume>74</volume><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2006.04.014</pub-id><pub-id pub-id-type="pmid">16730806</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>PW</given-names></name><name><surname>Chang</surname><given-names>FR</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Cheng</surname><given-names>PW</given-names></name><name><surname>Chiang</surname><given-names>LC</given-names></name><name><surname>Zeng</surname><given-names>FL</given-names></name><name><surname>Lin</surname><given-names>KH</given-names></name><name><surname>Wu</surname><given-names>YC</given-names></name></person-group><article-title>2-Substituted benzoxazinone analogues as anti-human coronavirus (anti-HCoV) and ICAM-1 expression inhibition agents</article-title><source>Bioorg Med Chem Lett</source><year>2004</year><volume>14</volume><fpage>4751</fpage><lpage>4754</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2004.06.083</pub-id><?supplied-pmid 7126427?><pub-id pub-id-type="pmid">15324901</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Hwang</surname><given-names>KC</given-names></name><name><surname>Chao</surname><given-names>CL</given-names></name><name><surname>Chang</surname><given-names>SG</given-names></name><name><surname>Ho</surname><given-names>MS</given-names></name><name><surname>Chou</surname><given-names>P</given-names></name></person-group><article-title>Can herbal medicine assist against avian flu? Learning from the experience of using supplementary treatment with Chinese medicine on SARS or SARS-like infectious disease in 2003</article-title><source>J Altern Complement Med</source><year>2006</year><volume>12</volume><fpage>505</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1089/acm.2006.12.505</pub-id><pub-id pub-id-type="pmid">16884338</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Hwang</surname><given-names>KC</given-names></name><name><surname>Chao</surname><given-names>CL</given-names></name><name><surname>Chang</surname><given-names>SG</given-names></name><name><surname>Ker</surname><given-names>CC</given-names></name><name><surname>Chien</surname><given-names>LC</given-names></name><name><surname>Ho</surname><given-names>MS</given-names></name><name><surname>Lin</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Chou</surname><given-names>P</given-names></name></person-group><article-title>The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients</article-title><source>Am J Chin Med</source><year>2006</year><volume>34</volume><fpage>927</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1142/S0192415X06004405</pub-id><pub-id pub-id-type="pmid">17163582</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>IC</given-names></name><name><surname>Bosch</surname><given-names>BJ</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Ghiran</surname><given-names>S</given-names></name><name><surname>Vasilieva</surname><given-names>N</given-names></name><name><surname>Dermody</surname><given-names>TS</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name></person-group><article-title>SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>3198</fpage><lpage>3203</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508381200</pub-id><pub-id pub-id-type="pmid">16339146</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>JB</given-names></name></person-group><article-title>Applications of the phytomedicine <italic>Echinacea purpurea</italic> (purple coneflower) in infectious diseases</article-title><source>Biomed Res Int</source><year>2012</year><volume>2012</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1155/2012/769896</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>SS</given-names></name><name><surname>Chung</surname><given-names>HY</given-names></name><name><surname>Choi</surname><given-names>JS</given-names></name></person-group><article-title>Inhibitory activities of <italic>Cassia tora</italic> and its anthraquinone constituents on angiotensin-converting enzyme</article-title><source>Phytother Res</source><year>2009</year><volume>23</volume><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1002/ptr.2579</pub-id><pub-id pub-id-type="pmid">18803227</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Min</surname><given-names>H</given-names></name></person-group><article-title>Ginseng, the natural effectual antiviral: protective effects of Korean red ginseng against viral infection</article-title><source>J Ginseng Res</source><year>2016</year><volume>40</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.jgr.2015.09.002</pub-id><pub-id pub-id-type="pmid">27746682</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>MT</given-names></name><name><surname>Sarkar</surname><given-names>C</given-names></name><name><surname>El-Kersh</surname><given-names>DM</given-names></name><name><surname>Jamaddar</surname><given-names>S</given-names></name><name><surname>Uddin</surname><given-names>SJ</given-names></name><name><surname>Shilpi</surname><given-names>JA</given-names></name><name><surname>Mubarak</surname><given-names>MS</given-names></name></person-group><article-title>Natural products and their derivatives against coronavirus: a review of the non-clinical and pre-clinical data</article-title><source>Phytother Res</source><year>2020</year><volume>2020</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/ptr.6700</pub-id></element-citation></ref><ref id="CR48"><mixed-citation publication-type="other">Kadhila NP, Sekhoacha M, Tselanyane M, Chinsembu KC, Molefe-Khamanga DM (2020) Determination of the antiplasmodial activity, cytotoxicity and active compound of <italic>Pechuel-loeschea leubnitziae</italic> O. Hoffm. (Asteraceae) of Namibia. SN Appl Sci 2. 10.1007/s42452-020-2926-6</mixed-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keum</surname><given-names>YS</given-names></name><name><surname>Jeong</surname><given-names>YJ</given-names></name></person-group><article-title>Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target</article-title><source>Biochem Pharmacol</source><year>2012</year><volume>84</volume><fpage>1351</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2012.08.012</pub-id><?supplied-pmid 7092843?><pub-id pub-id-type="pmid">22935448</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E</given-names></name><name><surname>Vijgen</surname><given-names>L</given-names></name><name><surname>Pannecouque</surname><given-names>C</given-names></name><name><surname>Van Damme</surname><given-names>E</given-names></name><name><surname>Peumans</surname><given-names>W</given-names></name><name><surname>Egberink</surname><given-names>H</given-names></name><name><surname>Balzarini</surname><given-names>J</given-names></name><name><surname>Van Ranst</surname><given-names>M</given-names></name></person-group><article-title>Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle</article-title><source>Antivir Res</source><year>2007</year><volume>75</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2007.03.003</pub-id><pub-id pub-id-type="pmid">17428553</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DE</given-names></name><name><surname>Min</surname><given-names>JS</given-names></name><name><surname>Jang</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Shin</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>CM</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>YH</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name></person-group><article-title>Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells</article-title><source>Biomol</source><year>2019</year><volume>9</volume><fpage>696</fpage><pub-id pub-id-type="doi">10.3390/biom9110696</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Eo</surname><given-names>EY</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name></person-group><article-title>Medicinal herbal extracts of <italic>Sophorae radix</italic>, <italic>Acanthopanacis cortex</italic>, <italic>Sanguisorbae radix</italic> and <italic>Torilis fructus</italic> inhibit coronavirus replication <italic>in vitro</italic></article-title><source>Antivir Ther</source><year>2010</year><volume>15</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.3851/IMP1615</pub-id><pub-id pub-id-type="pmid">20710051</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Yun</surname><given-names>YG</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name></person-group><article-title><italic>In vitro</italic> inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, <italic>Cimicifuga rhizoma</italic>, <italic>Meliae cortex</italic>, <italic>Coptidis rhizoma</italic>, and <italic>Phellodendron cortex</italic></article-title><source>J Clin Virol</source><year>2008</year><volume>41</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2007.10.011</pub-id><pub-id pub-id-type="pmid">18036887</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Shim</surname><given-names>SH</given-names></name><name><surname>Yang</surname><given-names>JL</given-names></name><name><surname>Oh</surname><given-names>WK</given-names></name></person-group><article-title>Antiviral escin derivatives from the seeds of <italic>Aesculus turbinata</italic> Blume (Japanese horse chestnut)</article-title><source>Bioorg Med Chem Lett</source><year>2017</year><volume>27</volume><fpage>3019</fpage><lpage>3025</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.05.022</pub-id><?supplied-pmid 7127610?><pub-id pub-id-type="pmid">28527823</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Tandi</surname><given-names>TE</given-names></name><name><surname>Choi</surname><given-names>JW</given-names></name><name><surname>Moon</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications</article-title><source>J Hosp Infect</source><year>2017</year><volume>95</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2016.10.008</pub-id><pub-id pub-id-type="pmid">28153558</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Huan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name></person-group><article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus&#x02013;induced lung injury</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>875</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1038/nm1267</pub-id><?supplied-pmid 16007097?><pub-id pub-id-type="pmid">16007097</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>SA</given-names></name><name><surname>Nagarajan</surname><given-names>SK</given-names></name><name><surname>Ramesh</surname><given-names>V</given-names></name><name><surname>Palaniyandi</surname><given-names>V</given-names></name><name><surname>Selvam</surname><given-names>SP</given-names></name><name><surname>Madhavan</surname><given-names>T</given-names></name></person-group><article-title>Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein</article-title><source>J Mol Struct</source><year>2020</year><volume>1221</volume><fpage>128823</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128823</pub-id><?supplied-pmid 7334662?><pub-id pub-id-type="pmid">32834111</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaki</surname><given-names>Y</given-names></name><name><surname>Wandersee</surname><given-names>MK</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Simmons</surname><given-names>G</given-names></name><name><surname>Nelson</surname><given-names>NM</given-names></name><name><surname>Bailey</surname><given-names>KW</given-names></name><name><surname>Vest</surname><given-names>ZG</given-names></name><name><surname>Li</surname><given-names>JK</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Smee</surname><given-names>DF</given-names></name></person-group><article-title>Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, <italic>Urtica dioic</italic>a agglutinin</article-title><source>Antivir Res</source><year>2011</year><volume>90</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.02.003</pub-id><pub-id pub-id-type="pmid">21338626</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Ryu</surname><given-names>YB</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name><name><surname>Rho</surname><given-names>MC</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>KO</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name></person-group><article-title><italic>In vitro</italic> antiviral activity of phlorotannins isolated from <italic>Ecklonia cava</italic> against porcine epidemic diarrhea coronavirus infection and hemagglutination</article-title><source>Bioorg Med Chem</source><year>2013</year><volume>21</volume><fpage>4706</fpage><lpage>4713</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.04.085</pub-id><?supplied-pmid 7127107?><pub-id pub-id-type="pmid">23746631</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laport</surname><given-names>MS</given-names></name><name><surname>Santos</surname><given-names>OCS</given-names></name><name><surname>Muricy</surname><given-names>G</given-names></name></person-group><article-title>Marine sponges: potential sources of new antimicrobial drugs</article-title><source>Curr Pharm Biotechnol</source><year>2009</year><volume>10</volume><fpage>86</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.2174/138920109787048625</pub-id><pub-id pub-id-type="pmid">19149592</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>TF</given-names></name><name><surname>Leung</surname><given-names>PC</given-names></name><name><surname>Wong</surname><given-names>EL</given-names></name><name><surname>Fong</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>KF</given-names></name><name><surname>Zhang</surname><given-names>SC</given-names></name><name><surname>Lam</surname><given-names>CW</given-names></name><name><surname>Wong</surname><given-names>V</given-names></name><name><surname>Choy</surname><given-names>KM</given-names></name><name><surname>Ko</surname><given-names>WM</given-names></name></person-group><article-title>Using herbal medicine as a means of prevention experience during the SARS crisis</article-title><source>Am J Chin Med</source><year>2005</year><volume>33</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1142/S0192415X05002965</pub-id><pub-id pub-id-type="pmid">16047553</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C</given-names></name></person-group><article-title>Griffithsin, a highly potent broad-spectrum antiviral lectin from red algae: from discovery to clinical application</article-title><source>Mar Drugs</source><year>2019</year><volume>17</volume><fpage>567</fpage><pub-id pub-id-type="doi">10.3390/md17100567</pub-id><?supplied-pmid 6835697?><pub-id pub-id-type="pmid">6835697</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>MY</given-names></name><name><surname>Shim</surname><given-names>BJ</given-names></name><name><surname>Youn</surname><given-names>HJ</given-names></name><name><surname>Hwang</surname><given-names>HJ</given-names></name><name><surname>Shin</surname><given-names>HC</given-names></name><name><surname>Jeon</surname><given-names>HK</given-names></name></person-group><article-title>Effects of <italic>Ecklonia cava</italic> polyphenol in individuals with hypercholesterolemia: a pilot study</article-title><source>J Med Food</source><year>2012</year><volume>15</volume><fpage>1038</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1089/jmf.2011.1996</pub-id><pub-id pub-id-type="pmid">23126663</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YZ</given-names></name><name><surname>Yang</surname><given-names>CW</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Qiu</surname><given-names>YQ</given-names></name><name><surname>Yeh</surname><given-names>TK</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Chao</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name></person-group><article-title>Synthesis and biological evaluation of tylophorine-derived dibenzoquinolines as orally active agents: exploration of the role of tylophorine e ring on biological activity</article-title><source>J Med Chem</source><year>2012</year><volume>55</volume><fpage>10363</fpage><lpage>10377</lpage><pub-id pub-id-type="doi">10.1021/jm300705j</pub-id><pub-id pub-id-type="pmid">23167614</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>PC</given-names></name></person-group><article-title>The efficacy of Chinese medicine for SARS: a review of Chinese publications after the crisis</article-title><source>Am J Chin Med</source><year>2007</year><volume>35</volume><fpage>575</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1142/S0192415X07005077</pub-id><pub-id pub-id-type="pmid">17708624</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YQ</given-names></name><name><surname>Li</surname><given-names>ZL</given-names></name><name><surname>Zhao</surname><given-names>WJ</given-names></name><name><surname>Wen</surname><given-names>RX</given-names></name><name><surname>Meng</surname><given-names>QW</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication</article-title><source>Eur J Med Chem</source><year>2006</year><volume>41</volume><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2006.03.024</pub-id><?supplied-pmid 7119042?><pub-id pub-id-type="pmid">16875760</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Pan</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title>Coronavirus infections and immune responses</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1002/jmv.25685</pub-id><?supplied-pmid 7166547?><pub-id pub-id-type="pmid">31981224</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>HQ</given-names></name><name><surname>Guo</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>SN</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>PG</given-names></name><name><surname>Li</surname><given-names>RS</given-names></name></person-group><article-title>Identification of natural compounds with antiviral activities against SARS-associated coronavirus</article-title><source>Antivir Res</source><year>2005</year><volume>67</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.02.007</pub-id><pub-id pub-id-type="pmid">15885816</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Nishiura</surname><given-names>K</given-names></name><name><surname>Ng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Extracts of the medicinal herb <italic>Sanguisorba officinalis</italic> inhibit the entry of human immunodeficiency virus-1</article-title><source>J Food Drug Anal</source><year>2013</year><volume>21</volume><fpage>S52</fpage><lpage>S58</lpage><pub-id pub-id-type="doi">10.1016/j.jfda.2013.09.034</pub-id><?supplied-pmid 4151571?><pub-id pub-id-type="pmid">4151571</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CW</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Ho</surname><given-names>TY</given-names></name><name><surname>Hsieh</surname><given-names>CC</given-names></name><name><surname>Chao</surname><given-names>PD</given-names></name></person-group><article-title>Anti-SARS coronavirus 3C-like protease effects of <italic>Isatis indigotica</italic> root and plant-derived phenolic compounds</article-title><source>Antivir Res</source><year>2005</year><volume>68</volume><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.07.002</pub-id><pub-id pub-id-type="pmid">16115693</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Chuo</surname><given-names>WH</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name></person-group><article-title>Effective inhibition of MERS-CoV infection by resveratrol</article-title><source>BMC Infect Dis</source><year>2017</year><volume>17</volume><fpage>144</fpage><pub-id pub-id-type="doi">10.1186/s12879-017-2253-8</pub-id><?supplied-pmid 5307780?><pub-id pub-id-type="pmid">28193191</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>CQ</given-names></name></person-group><article-title>Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)</article-title><source>J Integr Med</source><year>2020</year><volume>18</volume><fpage>87</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.joim.2020.02.004</pub-id><?supplied-pmid 7129043?><pub-id pub-id-type="pmid">32122812</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Manheimer</surname><given-names>E</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Gluud</surname><given-names>C</given-names></name></person-group><article-title>Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis</article-title><source>J Altern Complement Med</source><year>2004</year><volume>10</volume><fpage>1041</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1089/acm.2004.10.1041</pub-id><pub-id pub-id-type="pmid">15674000</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS)</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>10</volume><fpage>1465</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1002/14651858.CD004882.pub3</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Ning</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group><article-title>The roles of direct recognition by animal lectins in antiviral immunity and viral pathogenesis</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>2272</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.3390/molecules20022272</pub-id><?supplied-pmid 6272511?><pub-id pub-id-type="pmid">25642837</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loizzo</surname><given-names>MR</given-names></name><name><surname>Saab</surname><given-names>AM</given-names></name><name><surname>Tundis</surname><given-names>R</given-names></name><name><surname>Statti</surname><given-names>GA</given-names></name><name><surname>Menichini</surname><given-names>F</given-names></name><name><surname>Lampronti</surname><given-names>I</given-names></name><name><surname>Gambari</surname><given-names>R</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Phytochemical analysis and <italic>in vitro</italic> antiviral activities of the essential oils of seven Lebanon species</article-title><source>Chem Biodivers</source><year>2008</year><volume>5</volume><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1002/cbdv.200890045</pub-id><?supplied-pmid 7161995?><pub-id pub-id-type="pmid">18357554</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><?supplied-pmid 7159086?><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="CR78"><mixed-citation publication-type="other">Mahapatra AD, Bhowmik P, Banerjee A, Das A, Ojha D, Chattopadhyay D (2019) Ethnomedicinal wisdom: an approach for antiviral drug development. In New look to phytomedicine (pp. 35-61), Academic Press. 10.1016/B978-0-12-814619-4.00003-3</mixed-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarty</surname><given-names>MF</given-names></name><name><surname>DiNicolantonio</surname><given-names>JJ</given-names></name></person-group><article-title>Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus</article-title><source>Prog Cardiovasc Dis</source><year>2020</year><volume>63</volume><fpage>383</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2020.02.007</pub-id><?supplied-pmid 7130854?><pub-id pub-id-type="pmid">32061635</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercorelli</surname><given-names>B</given-names></name><name><surname>Pal&#x000f9;</surname><given-names>G</given-names></name><name><surname>Loregian</surname><given-names>A</given-names></name></person-group><article-title>Drug repurposing for viral infectious diseases: how far are we?</article-title><source>Trends Microbiol</source><year>2018</year><volume>6</volume><fpage>865</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.04.004</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>M</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names><suffix>Jr</suffix></name></person-group><article-title>Investigation of the influence of EPs&#x000ae; 7630, a herbal drug preparation from <italic>Pelargonium sidoides</italic>, on replication of a broad panel of respiratory viruses</article-title><source>Phytomedicine</source><year>2011</year><volume>18</volume><fpage>384</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2010.09.008</pub-id><pub-id pub-id-type="pmid">21036571</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>CA</given-names></name><name><surname>Ramessar</surname><given-names>K</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>BR</given-names></name></person-group><article-title>Antiviral lectins: selective inhibitors of viral entry</article-title><source>Antivir Res</source><year>2017</year><volume>142</volume><fpage>37</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.03.007</pub-id><pub-id pub-id-type="pmid">28322922</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mofolo</surname><given-names>MJ</given-names></name><name><surname>Kadhila</surname><given-names>P</given-names></name><name><surname>Chinsembu</surname><given-names>KC</given-names></name><name><surname>Mashele</surname><given-names>S</given-names></name><name><surname>Sekhoacha</surname><given-names>M</given-names></name></person-group><article-title>Green synthesis of silver nanoparticles from extracts of <italic>Pechuel-loeschea leubnitziae</italic>: their anti-proliferative activity against the U87 cell line</article-title><source>Inorg Nano-Met Chem</source><year>2020</year><volume>50</volume><fpage>949</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1080/24701556.2020.1729191</pub-id></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morigiwa</surname><given-names>A</given-names></name><name><surname>Kitabatake</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>Y</given-names></name><name><surname>Ikekawa</surname><given-names>N</given-names></name></person-group><article-title>Angiotensin converting enzyme&#x02013;inhibitory triterpens from <italic>Ganoderma lucidum</italic></article-title><source>Chem Pharm Bull</source><year>1986</year><volume>34</volume><fpage>3025</fpage><lpage>3028</lpage><pub-id pub-id-type="doi">10.1248/cpb.34.3025</pub-id><pub-id pub-id-type="pmid">3021351</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Schulte</surname><given-names>FW</given-names></name><name><surname>Lange-Gr&#x000fc;nweller</surname><given-names>K</given-names></name><name><surname>Obermann</surname><given-names>W</given-names></name><name><surname>Madhugiri</surname><given-names>R</given-names></name><name><surname>Pleschka</surname><given-names>S</given-names></name><name><surname>Ziebuhr</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>RK</given-names></name><name><surname>Gr&#x000fc;nweller</surname><given-names>A</given-names></name></person-group><article-title>Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses</article-title><source>Antivir Res</source><year>2018</year><volume>150</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.12.010</pub-id><pub-id pub-id-type="pmid">29258862</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngwa</surname><given-names>W</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Lyerly</surname><given-names>W</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Reid</surname><given-names>TE</given-names></name><name><surname>Lowe</surname><given-names>H</given-names></name><name><surname>Toyang</surname><given-names>N</given-names></name></person-group><article-title>Potential of flavonoid-inspired phytomedicines against COVID-19</article-title><source>Molecules</source><year>2020</year><volume>25</volume><fpage>2707</fpage><pub-id pub-id-type="doi">10.3390/molecules25112707</pub-id><?supplied-pmid 7321405?><pub-id pub-id-type="pmid">7321405</pub-id></element-citation></ref><ref id="CR87"><mixed-citation publication-type="other">Orhan IE, Tumen I (2015) Potential of <italic>Cupressus sempervirens</italic> (Mediterranean cypress) in health. In The Mediterranean diet (pp. 639-647). Academic Press. 10.1016/B978-0-12-407849-9.00057-9</mixed-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Jeong</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Ryu</surname><given-names>YB</given-names></name></person-group><article-title>Diarylheptanoids from <italic>Alnus japonica</italic> inhibit papain-like protease of severe acute respiratory syndrome coronavirus</article-title><source>Biol Pharm Bull</source><year>2012</year><volume>35</volume><fpage>2036</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1248/bpb.b12-00623</pub-id><pub-id pub-id-type="pmid">22971649</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Jeong</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Ryu</surname><given-names>YB</given-names></name></person-group><article-title>Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases</article-title><source>Bioorg Med Chem</source><year>2012</year><volume>20</volume><fpage>5928</fpage><lpage>5935</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2012.07.038</pub-id><?supplied-pmid 7127169?><pub-id pub-id-type="pmid">22884354</pub-id></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kwon</surname><given-names>JM</given-names></name><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Jeong</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Ryu</surname><given-names>YB</given-names></name></person-group><article-title>Dieckol, a SARS-CoV 3CL<sup>pro</sup> inhibitor, isolated from the edible brown algae <italic>Ecklonia cava</italic></article-title><source>Bioorg Med Chem</source><year>2013</year><volume>21</volume><fpage>3730</fpage><lpage>3737</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.04.026</pub-id><?supplied-pmid 7126891?><pub-id pub-id-type="pmid">23647823</pub-id></element-citation></ref><ref id="CR91"><mixed-citation publication-type="other">Pasdaran A, Pasdaran A Sheikhi D (2016) Volatile oils: potential agents for the treatment of respiratory infections. In: Kon K, Rai M (eds) The microbiology of respiratory system infections. Academic Press, pp. 237&#x02013;261. 10.1016/B978-0-12-804543-5.00016-6</mixed-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillaiyar</surname><given-names>T</given-names></name><name><surname>Meenakshisundaram</surname><given-names>S</given-names></name><name><surname>Manickam</surname><given-names>M</given-names></name></person-group><article-title>Recent discovery and development of inhibitors targeting coronaviruses</article-title><source>Drug Discov Today</source><year>2020</year><volume>25</volume><fpage>668</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.01.015</pub-id><?supplied-pmid 7102522?><pub-id pub-id-type="pmid">32006468</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polansky</surname><given-names>H</given-names></name><name><surname>Lori</surname><given-names>G</given-names></name></person-group><article-title>Coronavirus (COVID-19), first indication of efficacy of gene-eden-VIR/novirin in SARS-CoV-2 infections</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><fpage>105971</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105971</pub-id><?supplied-pmid 7146686?><pub-id pub-id-type="pmid">32283177</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinsloo</surname><given-names>G</given-names></name><name><surname>Marokane</surname><given-names>CK</given-names></name><name><surname>Street</surname><given-names>RA</given-names></name></person-group><article-title>Anti-HIV activity of southern African plants: current developments, phytochemistry and future research</article-title><source>J Ethnopharmacol</source><year>2018</year><volume>210</volume><fpage>133</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.08.005</pub-id><pub-id pub-id-type="pmid">28807850</pub-id></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastogi</surname><given-names>S</given-names></name><name><surname>Pandey</surname><given-names>MM</given-names></name><name><surname>Rawat</surname><given-names>AKS</given-names></name></person-group><article-title>Medicinal plants of the genus <italic>Betula</italic>&#x02014;traditional uses and a phytochemical&#x02013;pharmacological review</article-title><source>J Ethnopharmacol</source><year>2015</year><volume>159</volume><fpage>62</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2014.11.010</pub-id><pub-id pub-id-type="pmid">25449458</pub-id></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remuzzi</surname><given-names>A</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name></person-group><article-title>COVID-19 and Italy: what next?</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1225</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30627-9</pub-id><?supplied-pmid 32178769?><pub-id pub-id-type="pmid">32178769</pub-id></element-citation></ref><ref id="CR97"><mixed-citation publication-type="other">Rondanelli M, Miccono A, Lamburghini S, Avanzato I, Riva A, Allegrini P, Faliva MA, Peroni G, Nichetti M, Perna S (2018) Self-care for common colds: the pivotal role of vitamin D, vitamin C, zinc, and <italic>Echinacea</italic> in three main immune interactive clusters (physical barriers, innate and adaptive immunity) involved during an episode of common colds&#x02014;practical advice on dosages and on the time to take these nutrients/botanicals in order to prevent or treat common colds. Evid Based Complement Alternat Med. 10.1155/2018/5813095</mixed-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>P</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Lycorine: a prospective natural lead for anticancer drug discovery</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>107</volume><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.07.147</pub-id><?supplied-pmid 7127747?><pub-id pub-id-type="pmid">30114645</pub-id></element-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>YB</given-names></name><name><surname>Jeong</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Naguyen</surname><given-names>TT</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Rho</surname><given-names>MC</given-names></name></person-group><article-title>Biflavonoids from <italic>Torreya nucifera</italic> displaying SARS-CoV 3CL<sup>pro</sup> inhibition</article-title><source>Bioorg Med Chem</source><year>2010</year><volume>18</volume><fpage>7940</fpage><lpage>7947</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.09.035</pub-id><?supplied-pmid 7126309?><pub-id pub-id-type="pmid">20934345</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>YB</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Seo</surname><given-names>WD</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Rho</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name></person-group><article-title>SARS-CoV 3CL<sup>pro</sup> inhibitory effects of quinone-methide triterpenes from <italic>Tripterygium regelii</italic></article-title><source>Bioorg Med Chem Lett</source><year>2010</year><volume>20</volume><fpage>1873</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.01.152</pub-id><?supplied-pmid 7127101?><pub-id pub-id-type="pmid">20167482</pub-id></element-citation></ref><ref id="CR101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salinas</surname><given-names>FM</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>L</given-names></name><name><surname>Gentilini</surname><given-names>MV</given-names></name><name><surname>Regueira</surname><given-names>E</given-names></name><name><surname>Jodar</surname><given-names>MS</given-names></name><name><surname>Viegas</surname><given-names>M</given-names></name><name><surname>Michelini</surname><given-names>FM</given-names></name><name><surname>Hermida</surname><given-names>G</given-names></name><name><surname>Alch&#x000e9;</surname><given-names>LE</given-names></name><name><surname>Bueno</surname><given-names>CA</given-names></name></person-group><article-title><italic>Aesculus hippocastanum</italic> L. seed extract shows virucidal and antiviral activities against respiratory syncytial virus (RSV) and reduces lung inflammation <italic>in vivo</italic></article-title><source>Antivir Res</source><year>2019</year><volume>164</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.01.018</pub-id><pub-id pub-id-type="pmid">30711418</pub-id></element-citation></ref><ref id="CR102"><mixed-citation publication-type="other">Schapowal DA (2020) Use of Echinaforce to prevent coronavirus infections. EC Microbiol SI 2:23&#x02013;25. <ext-link ext-link-type="uri" xlink:href="http://www.sspm.org/smgp/homeindex/forschungf/2020/Schapowal.pdf">http://www.sspm.org/smgp/homeindex/forschungf/2020/Schapowal.pdf</ext-link></mixed-citation></ref><ref id="CR103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semwal</surname><given-names>DK</given-names></name><name><surname>Semwal</surname><given-names>RB</given-names></name><name><surname>Combrinck</surname><given-names>S</given-names></name><name><surname>Viljoen</surname><given-names>A</given-names></name></person-group><article-title>Myricetin: a dietary molecule with diverse biological activities</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.3390/nu8020090</pub-id><?supplied-pmid 4772053?><pub-id pub-id-type="pmid">26891321</pub-id></element-citation></ref><ref id="CR104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Soloveva</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name></person-group><article-title>Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes</article-title><source>Sci Adv</source><year>2018</year><volume>4</volume><fpage>eaau8408</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aau8408</pub-id><?supplied-pmid 6248931?><pub-id pub-id-type="pmid">30474060</pub-id></element-citation></ref><ref id="CR105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>G</given-names></name><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>Glowacka</surname><given-names>I</given-names></name><name><surname>Steffen</surname><given-names>I</given-names></name><name><surname>Chaipan</surname><given-names>C</given-names></name><name><surname>Agudelo</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Rennekamp</surname><given-names>AJ</given-names></name><name><surname>Hofmann</surname><given-names>H</given-names></name><name><surname>Bates</surname><given-names>P</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S</given-names></name></person-group><article-title>Different host cell proteases activate the SARS-coronavirus spike-protein for cell&#x02013;cell and virus&#x02013;cell fusion</article-title><source>Virology</source><year>2011</year><volume>413</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2011.02.020</pub-id><?supplied-pmid 3086175?><pub-id pub-id-type="pmid">21435673</pub-id></element-citation></ref><ref id="CR106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>G</given-names></name><name><surname>Gosalia</surname><given-names>DN</given-names></name><name><surname>Rennekamp</surname><given-names>AJ</given-names></name><name><surname>Reeves</surname><given-names>JD</given-names></name><name><surname>Diamond</surname><given-names>SL</given-names></name><name><surname>Bates</surname><given-names>P</given-names></name></person-group><article-title>Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>11876</fpage><lpage>11881</lpage><pub-id pub-id-type="doi">10.1073/pnas.0505577102</pub-id><?supplied-pmid 1188015?><pub-id pub-id-type="pmid">16081529</pub-id></element-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir ul Qamar</surname><given-names>M</given-names></name><name><surname>Alqahtani</surname><given-names>SM</given-names></name><name><surname>Alamri</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name></person-group><article-title>Structural basis of SARS-CoV-2 3CL<sup>pro</sup> and anti-COVID-19 drug discovery from medicinal plants</article-title><source>J Pharm Anal</source><year>2020</year><volume>10</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id><?supplied-pmid 7156227?><pub-id pub-id-type="pmid">32296570</pub-id></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theisen</surname><given-names>LL</given-names></name><name><surname>Muller</surname><given-names>CP</given-names></name></person-group><article-title>EPs&#x000ae; 7630 (Umckaloabo&#x000ae;), an extract from <italic>Pelargonium sidoides</italic> roots, exerts anti-influenza virus activity <italic>in vitro</italic> and in vivo</article-title><source>Antivir Res</source><year>2012</year><volume>94</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.03.006</pub-id><pub-id pub-id-type="pmid">22475498</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vellingiri</surname><given-names>B</given-names></name><name><surname>Jayaramayya</surname><given-names>K</given-names></name><name><surname>Iyer</surname><given-names>M</given-names></name><name><surname>Narayanasamy</surname><given-names>A</given-names></name><name><surname>Govindasamy</surname><given-names>V</given-names></name><name><surname>Giridharan</surname><given-names>B</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Venugopal</surname><given-names>A</given-names></name><name><surname>Venkatesan</surname><given-names>D</given-names></name><name><surname>Ganesan</surname><given-names>H</given-names></name><name><surname>Rajagopalan</surname></name></person-group><article-title>COVID-19: a promising cure for the global panic</article-title><source>Sci Total Environ</source><year>2020</year><volume>725</volume><fpage>138277</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138277</pub-id><?supplied-pmid 7128376?><pub-id pub-id-type="pmid">32278175</pub-id></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>R</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title><source>J Virol</source><year>2020</year><volume>94</volume><fpage>e00127</fpage><lpage>e00120</lpage><pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id><?supplied-pmid 7081895?><pub-id pub-id-type="pmid">31996437</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>HM</given-names></name><name><surname>Li</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name></person-group><article-title>Glycyrrhizic acid as the antiviral component of <italic>Glycyrrhiza uralensis</italic> Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease</article-title><source>J Ethnopharmacol</source><year>2013</year><volume>147</volume><fpage>114</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2013.02.017</pub-id><?supplied-pmid 7125661?><pub-id pub-id-type="pmid">23454684</pub-id></element-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>BB</given-names></name><name><surname>Song</surname><given-names>GQ</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>XM</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>FH</given-names></name></person-group><article-title>Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study</article-title><source>Eur J Med Chem</source><year>2017</year><volume>137</volume><fpage>450</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.05.045</pub-id><?supplied-pmid 7115414?><pub-id pub-id-type="pmid">28624700</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <italic>in vitro</italic></article-title><source>Cell Res</source><year>2020</year><volume>30</volume><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Subunit vaccines against emerging pathogenic human coronaviruses</article-title><source>Front Microbiol</source><year>2020</year><volume>11</volume><fpage>298</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.00298</pub-id><?supplied-pmid 7105881?><pub-id pub-id-type="pmid">32265848</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Quan</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name></person-group><article-title>A comparative study of <italic>Lonicera japonica</italic> with related species: morphological characteristics, ITS sequences and active compounds</article-title><source>Biochem Syst Ecol</source><year>2014</year><volume>54</volume><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.bse.2014.02.002</pub-id><?supplied-pmid 7117028?><pub-id pub-id-type="pmid">32287929</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>CC</given-names></name><name><surname>Kuo</surname><given-names>YH</given-names></name><name><surname>Jan</surname><given-names>JT</given-names></name><name><surname>Liang</surname><given-names>PH</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Liu</surname><given-names>HG</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Chang</surname><given-names>ST</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Hou</surname><given-names>CC</given-names></name></person-group><article-title>Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus</article-title><source>J Med Chem</source><year>2007</year><volume>50</volume><fpage>4087</fpage><lpage>4095</lpage><pub-id pub-id-type="doi">10.1021/jm070295s</pub-id><pub-id pub-id-type="pmid">17663539</pub-id></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>CC</given-names></name><name><surname>Shyur</surname><given-names>LF</given-names></name><name><surname>Jan</surname><given-names>JT</given-names></name><name><surname>Liang</surname><given-names>PH</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>Arulselvan</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>JB</given-names></name><name><surname>Kuo</surname><given-names>SC</given-names></name><name><surname>Yang</surname><given-names>NS</given-names></name></person-group><article-title>Traditional Chinese medicine herbal extracts of <italic>Cibotium barometz</italic>, <italic>Gentiana scabra</italic>, <italic>Dioscorea batatas</italic>, <italic>Cassia tora</italic>, and <italic>Taxillus chinensis</italic> inhibit SARS-CoV replication</article-title><source>J Tradit Complement Med</source><year>2011</year><volume>1</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S2225-4110(16)30055-4</pub-id><?supplied-pmid 3942999?><pub-id pub-id-type="pmid">24716104</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>The management of coronavirus infections with particular reference to SARS</article-title><source>J Antimicrob Chemother</source><year>2008</year><volume>62</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn243</pub-id><?supplied-pmid 7109825?><pub-id pub-id-type="pmid">18565970</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name></person-group><article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</article-title><source>Acta Pharm Sin B</source><year>2020</year><volume>10</volume><fpage>766</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.02.008</pub-id><?supplied-pmid 7102550?><pub-id pub-id-type="pmid">32292689</pub-id></element-citation></ref><ref id="CR120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JG</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>YB</given-names></name><name><surname>Chen</surname><given-names>TQ</given-names></name><name><surname>Wong</surname><given-names>KH</given-names></name><name><surname>Wu</surname><given-names>JZ</given-names></name></person-group><article-title>Chemical composition, antimicrobial activity against <italic>Staphylococcus aureus</italic> and a pro-apoptotic effect in SGC-7901 of the essential oil from <italic>Toona sinensis</italic> (A. Juss.) Roem. leaves</article-title><source>J Ethnopharmacol</source><year>2014</year><volume>154</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2014.04.002</pub-id><?supplied-pmid 7126815?><pub-id pub-id-type="pmid">24726685</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Poole</surname><given-names>P</given-names></name></person-group><article-title>Traditional Chinese medicine in the treatment of acute respiratory tract infections</article-title><source>Respir Med</source><year>2008</year><volume>102</volume><fpage>1093</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2008.03.015</pub-id><?supplied-pmid 7134919?><pub-id pub-id-type="pmid">18590956</pub-id></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>PG</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>HS</given-names></name></person-group><article-title>Some research clues on Chinese herbal medicine for SARS prevention and treatment</article-title><source>China J Chin Mater Med</source><year>2003</year><volume>28</volume><fpage>481</fpage><lpage>483</lpage></element-citation></ref><ref id="CR123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CW</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>YZ</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name></person-group><article-title>The cardenolide ouabain suppresses coronaviral replication via augmenting a Na+/K+-ATPase-dependent PI3K_PDK1 axis signaling</article-title><source>Toxicol Appl Pharmacol</source><year>2018</year><volume>356</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2018.07.028</pub-id><?supplied-pmid 7103114?><pub-id pub-id-type="pmid">30053394</pub-id></element-citation></ref><ref id="CR124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Islam</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective</article-title><source>Int J Biol Sci</source><year>2020</year><volume>16</volume><fpage>1708</fpage><pub-id pub-id-type="doi">10.7150/ijbs.45538</pub-id><?supplied-pmid 7098036?><pub-id pub-id-type="pmid">32226288</pub-id></element-citation></ref><ref id="CR125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>CF</given-names></name><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Chiang</surname><given-names>LC</given-names></name><name><surname>Shieh</surname><given-names>DE</given-names></name><name><surname>Yen</surname><given-names>MH</given-names></name><name><surname>San Chang</surname><given-names>J</given-names></name></person-group><article-title>Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines</article-title><source>J Ethnopharmacol</source><year>2013</year><volume>148</volume><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2013.04.040</pub-id><pub-id pub-id-type="pmid">23643542</pub-id></element-citation></ref><ref id="CR126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Chin</surname><given-names>YW</given-names></name><name><surname>Jee</surname><given-names>JG</given-names></name><name><surname>Keum</surname><given-names>YS</given-names></name><name><surname>Jeong</surname><given-names>YJ</given-names></name></person-group><article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title><source>Bioorg Med Chem Lett</source><year>2012</year><volume>22</volume><fpage>4049</fpage><lpage>4054</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id><?supplied-pmid 7127438?><pub-id pub-id-type="pmid">22578462</pub-id></element-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>DH</given-names></name><name><surname>Wu</surname><given-names>KL</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>SQ</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name></person-group><article-title><italic>In silico</italic> screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</article-title><source>J Integr Med</source><year>2020</year><volume>18</volume><fpage>152</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.joim.2020.02.005</pub-id><?supplied-pmid 7102521?><pub-id pub-id-type="pmid">32113846</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Zhi</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>F</given-names></name></person-group><article-title>Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection</article-title><source>J Infect Dis</source><year>2005</year><volume>192</volume><fpage>1355</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1086/491479</pub-id><?supplied-pmid 7202438?><pub-id pub-id-type="pmid">16170752</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title><italic>Astragalus</italic> polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication</article-title><source>Microb Pathog</source><year>2018</year><volume>114</volume><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2017.11.026</pub-id><pub-id pub-id-type="pmid">29170045</pub-id></element-citation></ref><ref id="CR130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name></person-group><article-title>Anticomplementary principles of a Chinese multiherb remedy for the treatment and prevention of SARS</article-title><source>J Ethnopharmacol</source><year>2008</year><volume>117</volume><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2008.02.012</pub-id><?supplied-pmid 7126446?><pub-id pub-id-type="pmid">18400428</pub-id></element-citation></ref><ref id="CR131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ao</surname><given-names>Z</given-names></name><name><surname>Bello</surname><given-names>A</given-names></name><name><surname>Ran</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wigle</surname><given-names>J</given-names></name><name><surname>Kobinger</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name></person-group><article-title>Characterization of the inhibitory effect of an extract of <italic>Prunella vulgaris</italic> on Ebola virus glycoprotein (GP)-mediated virus entry and infection</article-title><source>Antivir Res</source><year>2016</year><volume>127</volume><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.01.001</pub-id><pub-id pub-id-type="pmid">26778707</pub-id></element-citation></ref><ref id="CR132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hasoksuz</surname><given-names>M</given-names></name><name><surname>Spiro</surname><given-names>D</given-names></name><name><surname>Halpin</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Stollar</surname><given-names>S</given-names></name><name><surname>Janies</surname><given-names>D</given-names></name><name><surname>Hadya</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Ghedin</surname><given-names>E</given-names></name><name><surname>Saif</surname><given-names>L</given-names></name></person-group><article-title>Complete genomic sequences, a key residue in the spike protein and deletions in nonstructural protein 3b of US strains of the virulent and attenuated coronaviruses, transmissible gastroenteritis virus and porcine respiratory coronavirus</article-title><source>Virol</source><year>2007</year><volume>358</volume><fpage>424</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.08.051</pub-id></element-citation></ref><ref id="CR133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name></person-group><article-title>Antiviral activity of Jinchai capsule against influenza virus</article-title><source>J Tradit Chin Med</source><year>2013</year><volume>33</volume><fpage>200</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S0254-6272(13)60125-9</pub-id><pub-id pub-id-type="pmid">23789217</pub-id></element-citation></ref><ref id="CR134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>N</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name></person-group><article-title>Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)</article-title><source>J Biol Chem</source><year>2016</year><volume>291</volume><fpage>9218</fpage><lpage>9232</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.716100</pub-id><?supplied-pmid 4861487?><pub-id pub-id-type="pmid">26953343</pub-id></element-citation></ref><ref id="CR135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Si</surname><given-names>HR</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>HD</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><?supplied-pmid 7095418?><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="CR136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Agudelo</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Goetz</surname><given-names>DH</given-names></name><name><surname>Hansell</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Roush</surname><given-names>WR</given-names></name><name><surname>McKerrow</surname><given-names>J</given-names></name><name><surname>Craik</surname><given-names>CS</given-names></name><name><surname>Amberg</surname><given-names>SM</given-names></name><name><surname>Simmons</surname><given-names>G</given-names></name></person-group><article-title>Inhibitors of SARS-CoV entry&#x02013;identification using an internally-controlled dual envelope pseudovirion assay</article-title><source>Antivir Res</source><year>2011</year><volume>92</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.07.016</pub-id><pub-id pub-id-type="pmid">21820471</pub-id></element-citation></ref><ref id="CR137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name></person-group><article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2</article-title><source>Cell Discovery</source><year>2020</year><volume>6</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id><?supplied-pmid 6952422?><pub-id pub-id-type="pmid">31934347</pub-id></element-citation></ref><ref id="CR138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Pfefferle</surname><given-names>S</given-names></name><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>Glowacka</surname><given-names>I</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S</given-names></name><name><surname>Simmons</surname><given-names>G</given-names></name></person-group><article-title>A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>8753</fpage><lpage>8764</lpage><pub-id pub-id-type="doi">10.1128/JVI.00554-10</pub-id><?supplied-pmid 2919028?><pub-id pub-id-type="pmid">20573835</pub-id></element-citation></ref><ref id="CR139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name></person-group><article-title>Chinese patent medicines in the treatment of coronavirus disease 2019 (COVID-19) in China</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>1066</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.01066</pub-id><?supplied-pmid 7396557?><pub-id pub-id-type="pmid">32848729</pub-id></element-citation></ref><ref id="CR140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>P</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Saitoh</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name></person-group><article-title>Procyanidins and butanol extract of cinnamomi cortex inhibit SARS-CoV infection</article-title><source>Antivir Res</source><year>2009</year><volume>82</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2009.02.001</pub-id><pub-id pub-id-type="pmid">19428598</pub-id></element-citation></ref></ref-list></back></article>